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1. General introduction and objectives of the study 
1.1 Aim of thesis 
Uveitis, an acute or chronic inflammation of the uveal 
tissue of the eye, and keratitis, an inflammation of corneal 
tissue, may have their cause in bacterial, protozoal or viral 
infection. No etiological agent can be found in some patients. In 
these cases therapy has to be of symptomatic nature. One of the 
major causes of destruction of ocular tissues in uveitis and 
keratitis is the production of lysosomal enzymes by infiltrating 
white blood cells. Inhibition of either cellular infiltration of 
tissue or the prevention of lysosomal enzyme release by these 
cells will lead to less destruction of ocular tissue. 
In this study we investigated the prevention of cellular 
infiltration of ocular tissue by topical or systemic 
administration of agents interfering with lipid mediators. 
An Arthus reaction (delayed hypersensitivity reaction) of 
the cornea or uvea of the rabbit eye can be initiated by 
injection of antigen in respectively the corneal stroma or 
vitreous body. The clinical symptoms of the subsequent antigen-
antibody reaction in the cornea are conjunctival hyperemia, an 
annular infiltration with leukocytes (ring of Wessely), stromal 
edema, and neovascularization of the cornea.l 
Symptoms of the Arthus reaction elicited by intravitreal 
injection of an antigen are blood-aqueous barrier breakdown 
(visible with a slitlamp as a flare) and the presence of 
infiltrated leukocytes in the anterior chamber and vitreous 
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body. 2 ' 3 
Phospholipid derivatives may act as mediators in human and 
animal inflammatory disease. These derivatives of cell membrane 
phospholipids are platelet-activating factor (PAF) and arachi-
donic acid. Arachidonic acid can be further metabolized to 
prostaglandins (PGs) and leukotrienes (LTs). 
Platelet-activating factor can be produced by embryo chick 
retina upon stimulation with neurotransmitters such as acetyl-
choline and dopamine.4 Systemic administration of PAF induces in 
the rabbit sludging in the retinal circulation and intense extra-
vasation of plasma proteins while on fluoroangiographic pictures 
severe retinopathy is visible.5 In addition (R)-PAF and lyse-
platelet-activating factor (lyso-PAF) significantly impair the 
b-wave of the electroretinogram of the isolated rat retina, and 
these effects are dose-dependently inhibited by specific PAF-
antagonists.6 A PAF-antagonist also inhibits the transient 
increase in intra-ocular pressure induced by laser iridial burns; 
such a phenomenon is not inhibited by indomethacin.? Specific 
receptors for PAF in iris and ciliary body have been 
determined. 8 ' 9 
Arachidonic acid can be metabolized by ocular tissues into 
PGs by the enzyme cyclooxygenase and into LTs by the enzyme 
5-lipoxygenase.l0-13 The role of PGs and LTs as mediator in the 
inflammatory response of the eye in generall4-16 and of the 
Arthus phenomenon in particular is well known.l?-19 The PG level 
may be lowered by inhibition of cyclooxygenase. Cyclooxygenase 
inhibitors, however, do not decrease the severity of an Arthus 
reaction of cornea or uvea but even stimulate the leukocyte 
infiltration of the eye in these inflammatory diseases.3,20-23 
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The enzyme 5-lipoxygenase produces among others LTB4 , a very 
potent chemotactic substance.24 In the eye its chemotactic 
potency has also been described.25,26 
The main theme of this thesis is about the role of lipid 
derived mediators in the Arthus phenomenon in the eye and the 
effect of pharmacological inhibition of these mediators. 
The role of a PAP-antagonist on corneal inflammation and the 
role of the second messenger cyclic adenosine monophosphate 
(cAMP) was investigated as well as the relative importance of 
lipoxygenase versus cyclooxygenase products in ocular 
inflammation. Phospolipase action in plasma membrane can make 
arachidonic acid available for conversion into cyclooxygenase or 
lipoxygenase products. Inhibition of arachidonic acid conversion 
to PGs may increase LTB production, which in part could be 
responsible for the aggravation of the Arthus reaction of the 
cornea or uvea. However, arachidonic acid can also be oxidized in 
mitochondria or used in esterification reactions, which at least 
in other tissues are of another order of magnitude. Inhibition of 
the ocular Arthus reaction by 5-lipoxygenase inhibitors is 
therefore of importance. 
The following possibilities for modulation of the production 
of PGs and LTs from arachidonic acid products that have been used 
are: 
- Replacement of arachidonic acid by a false substrate - colum-
binic acid. Columbinic acid replaces arachidonic acid in the 
cell membrane, but cannot be converted into prostaglandins or 
leukotrienes.27 
- Replacement of arachidonic acid by a competitive substrate like 
eicosapentaenoic acid. Formation of prostaglandins and leukotri-
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enes from eicosapentaenoic acid is possible, but these substances 
have a different biological effect compared to arachidonic acid 
derived products.28-31 
- Specific pharmacological inhibition of either cyclooxygenase 
or 5-lipoxygenase.32-34 
- Combined inhibition of the cyclooxygenase and 5-lipoxygenase 
enzymes or prevention of arachidonic acid release from cell 
membrane phospholipids.35,36 
1.2 Historical introduction 
1.2.1 Prostaglandins 
A series of elegant experiments led Sir Thomas Lewis in 1927 
to suggest that events in the acute inflammatory response were 
controlled by the local generation of chemical substances.37 
In 1930 Kurzak and Lieb, two New York gynecologists, discovered 
the smooth muscle-stimulating actions of seminal fluid on the 
human uterus.38 
The actions of seminal plasma on isolated smooth muscle were 
first reported by von Euler39-41 and independently by 
Goldblatt.42 The chemistry of the active substances was not known 
by these early workers and they were called prostaglandins (PGs) 
by von Euler simply as a reflection of the site of production, 
the prostate. 
In the mid 1960s, PGs were found to be oxidative metabolites 
of essential fatty acids, constituents of membrane 
phospholipids.43, 44 
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1.2.2 Leukotrienes 
In 1938 Feldberg and Kellaway showed that cobra venom 
injected into perfused.lungs caused the release of a substance 
which slowly induced sustained contractions of guinea pig 
jejunem. The contractions were different from those induced by 
histamine and the substance was referred to as slow reacting 
substance.45 A few years later it was demonstrated that a similar 
substance was released from the guinea pig pulmonary system upon 
immunological challenge.46 Brocklehurst named the substance "slow 
reacting substance in anaphylaxis" (SRS-A) .47 
It is now known that these substances are identical. Despite 
many attempts SRS and SRS-A resisted chemical identification 
until the end of the 1970s, although it was known to be a sulphur 
containing lipid. The breakthrough came in 1979 when Samuelson's 
research group discovered new metabolites of arachidonic acid 
through the lipoxygenase pathway with biological and chemical 
properties of SRS and SRS-A.48,49 These metabolites were named 
leukotrienes because they are produced by leukocytes and are 
characterized by the presence of three conjugated double bonds in 
the molecule. SRS and SRS-A have been shown to consist of a 
mixture of leukotrienes. 
1.2.3 Platelet-activating factor 
A reaction involving leukocytes and requiring antigen to 
trigger the release of histamine from rabbit platelets was 
reported in the sixties50- 52 and attributed to a factor actively 
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released from the leukocytes by a calcium- and temperature 
dependent process.53,54 In 1972 and later, Benveniste et al.SS-57 
described this substance and proposed the term platelet-
activating factor, initiated its characterization, and showed 
that it was released from rabbit basophils by an IgE-dependent 
process. 
This product has since been characterized as a phospolipase 
A2 (PLA2 )-sensitive phospholipid5 8 and further identified as 
1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (Fig. 1}59,60 
The ether-lipid was finally synthesized and became available for 
pharmacological studies.61 
Both PAF-acether (ace standing for acetate and ether for the 
ether bond) and AGEPC (acetyl glyceryl ether phosphoryl choline) 
are now used in the literature as synonyms for PAF. 
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2. Fatty acids as precursors of lipid mediators of inflammation 
2.1 Dietary fatty acids 
Fats form an important constituent of our diet. Dietary fats 
are mainly composed of triglycerides: a glycerol moiety with 
three fatty acids. There are many types of fatty acids, differing 
in chain length (number of carbon atoms) and in desaturation 
(number location and configuration of double bonds). 
Fatty acids also are constituents of phospholipids, a class 
of cell membrane structural lipids. Generally a phospolipid is 
composed of a glycerol molecule which is linked at two of its 
hydroxyl groups to a long-chain fatty acid. The third hydroxyl 
group is esterified to a phosphate group which in turn is linked 
to either choline, ethanolamine, serine or inositol. 
Recognition that some unsaturated fatty acids could not be 
synthetized by mammals led to the designation of essential and 
nonessential unsaturated fatty acids. 
"Properly, the term essential fatty acids should include 
only those substances which are active both for growth and for 
maintenance of dermal integrity, limiting the term to linoleic 
and arachidonic acids and to such other acids as may be derived 
metabolically from them".62 
Since the essential fatty acids are present in animal cell 
membranes any food containing such membranes will contain at 
least small amounts of most of the essential fatty acids. The 
main dietary sources of various essential fatty acids are as 
follows: 
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- Linoleic acid. This is present in substantial amounts in dairy 
products, organ meats such as liver, human milk and in many 
vegetable seed oils such as sunflower, safflower, corn and soy 
beans. 
- Gamma-linolenic acid. This is present in small amounts in human 
milk and fresh cow milk; larger amounts are found in the seed oil 
of the evening primrose. 
- Dihomo-gamma-linolenic acid. Moderate amounts are found in 
human milk. 
- Arachidonic acid. Human milk contains moderate amounts and cow 
milk small amounts. Meat, egg yolks, some seaweeds and some 
shrimps contain substantial amounts. 
- Eicosapentaenoic acid and docosahexaenoic acid are abundant in 
oily fish and shell fish, particularly from cold ocean areas.63 
2.2 Metabolism of fatty acids 
Incorporation of fatty acids in cell membrane phospolipids 
is accomplished either by replacement of de novo synthetized 
phospholipids or by replacement of the fatty acid part of a 
phospholipid by another fatty acid with the help of acyltransfer-
ase(s) after phospholipase action. There are at least two differ-
ent acyltransferases. Both types are widely but not equally 
distributed within the cells. One specifically attaches a satu-
rated fatty acid to the 1-position of a phospholipid molecule, 
the other acting at the 2-position of the molecule prefers 
unsaturated fatty acids.64 This may be one of the mechanisms 
responsible for the predominant occupation of the 2-position of 
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the glycerol moiety of phospholipids by unsaturated fatty acids. 
The biosynthesis of polyunsaturated fatty acids involves 
alternating desaturation and elongation reactions in which two 
hydrogen atoms are removed to create a new double bond and then 
two carbon atoms are added to lengthen the chain. Specific 
enzymes are required for each desaturation and elongation step, 
desaturases and elongases. 
The consequence is that polyunsaturated fatty acids can be 
grouped in families determined by the place of their first double 
bond. The most important families in mammalian physiology are the 
n-9, n-6 and n-3 families with the first double bond on the 9th, 
6th and 3rd carbon atom from the methyl end, respectively. 
Independent of any further desaturations or elongations unsatu-
rated fatty acids will remain within their family.65 The three 
series appear to compete with one another in a sense that for 
instance n-3 fatty acids can inhibit eicosanoid metabolism from 
n-6.67 
In this manner the desaturation and elongation processes can 
be influenced by dietary factors. In addition hormonal factors 
are known to influence these processes.66,67 
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3. Biosynthesis and action of lipid mediators 
3.1 Phospholipids 
3.1.1 Phospholipids as precursors of lipid mediators 
Eicosanoids is a general term used for the metabolites which 
are derived via oxidative metabolism of the fatty acid arachi-
donic acid(= eicosatetraenoic acid), eicosatrienoic acid 
(dihomo-gamma-linolenic acid) and eicosapentaenoic acid. They 
include prostaglandins, thromboxane, leukotrienes and other 
oxygenated fatty acid derivatives. Eicosanoids are generated in 
response to a wide variety of physiological and pharmacological 
stimuli and, since eicosanoids are not stored within cells, 
biosynthesis must immediately precede release. The precursor 
fatty acids can arise from the unesterified fatty acid pool but 
also by hydrolytic cleavage of intracellular lipid precursors: 
cholesteryl esters, mono- di- or tri-glycerides, and phospha-
tides. The phospholipid fraction constitutes the major intra-
cellular source of the eicosanoid precursors. Therefore our 
attention wil be focussed on metabolism as eicosanoid precursors 
of these lipids.68,69 
Platelet-activating factor is a phosphorus containing 
derivative of cell membrane phospholipids. Its metabolism will 
also be considered. 
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3.1.2 Phospholipases 
Phospholipases are a class of enzymes that catalyze the 
hydrolysis of membrane phospholipids to release free fatty acids 
or one of the four phosphorylated bases. 
In so far as they are relevant to the generation of the 
eicosanoids, phospholipids may be thought of as consisting of a 
three carbon glyceryl backbone to which fatty acids and 
phosphorylated bases are attached to the the glyceryl alchol by 
an ester linkage. The three positions on the glyceryl backbone 
are referred to as o( , B and 0( 1. Fatty acids are esterified on 
the ~and B position, whilst the o< 1 position is esterified 
either to phosphoric acid or to a phosphorylated base; phospha-
tidylcholine, phosphatidylethanolamine, phosphatidylserine or 
phosphatidylinositol. 
A fatty acid that is esterified in position ~ can be 
liberated by phospholipase A1 , one that is esterified in position 
B by phospholipase A2 and phospholipase C hydrolyses the 
glyceryl-phosphate bond to liberate a phosphorylated base. 
Because unsaturated fatty acids (this includes all eicosanoid 
precursors) are generally attached in B position to the glyceryl 
backbone phospholipase A2 becomes potentially the most important 
regulatory enzyme for the entire eicosanoid cascade.70,71 In 
addition to eicosanoids formed from arachidonic acid other 
phospholipase-derived products also have biological actions. 
Lysophospholipids, the co-products of phospholipase action are 
cytotoxic substances72 and have been implicated in several human 
inflammatory conditions.73,74 Acetylation of lysophospholipid at 
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the 2 hydroxy group gives rise to another lipid mediator, PAF-
acether, a potent platelet aggregating substance and inducer of 
various inflammatory reactions. Other important products of 
phospholipid breakdown involved in transmembrane signal 
transduction (for instance from phosphoinositol) will not be 
discussed here. 
3.1.3 Phospholipase inhibitors 
Compounds that inhibit phopholipase A2 may be subdivided 
into agents that inhibit the enzyme: a) by interacting directly 
with the enzyme; b) by interfering with the binding of the 
substrate; or c) by interacting or interfering with the binding 
of calcium ions. 
a) Enzyme inhibitors. 
Glucocorticoids inhibit phospholipase A2 activity as 
measured by the release of arachidonic acid. This correlates well 
with their anti-inflammatory activity. The steroids induce 
biosynthesis of the phospholipase A2 inhibitory protein35,75 now 
called lipocortin.76,77 Some compounds like para-bromophenacyl-
bromide and several natural products including glycerrhizin alpha 
tocopherol, polymycin B and manoalide, a sesquiterterpenoid 
isolated from a sponge, may inhibit phospholipase A2 
directly. 78 - 81 
b) Inhibitors interacting with the substrate. 
Compounds which form complexes with phospholipids can 
influence phospholipase action because the complex formation 
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prevents catalytic action by phospholipase A2 . Examples of these 
compounds are chlorpromazine, mepacrine and volatile anesthetics 
like halothane.82,83 Many amphiphilic compounds, as well as cold, 
may decrease membrane fluidity and prevent interaction of 
phospholipase(s) intercalated in the phospholipid bilayers of the 
biomembranes with their substates. 
3.2 Platelet-activating factor 
3.2.1 Pathophysiology of platelet-activating factor 
Over the last few years, several publications have indicated 
that platelet-activating factor (PAF = PAF-acether), is a major 
mediator of inflammation and anaphylaxis.84-86 PAF is produced by 
many types of stimulated cells including mononuclear phagocytes, 
basophils, platelets, endothelial cells and human polymorpho-
nuclear neutrophils (PMN).87-91 Its action was first thought to 
be restricted to platelet activation, but now it also seems to 
stimulate PMN function. Indeed, intravenous injection of purified 
PAF-acether into rabbits led both to the development of an acute 
neutropenia and to the formation of intravascular PMN aggre-
gates.92 It induces smooth muscle contraction,93 enhances 
vascular permeability,94,95 and leads to bronchoconstriction, 
hypotension and renal failure.84-87,96 
Numerous interactions between PAF and other lipid mediators 
have been described. For instance, PAF-acether induces the 
release of leukotriene c4 (LTC4 ) from rat lung and, when 
platelets are present, the release of prostaglandins. 
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3.2.2 Inhibition of platelet-activating factor action 
The discovery of potent and specific antagonists of PAF-
acether has recently allowed a more detailed analysis of the role 
of this phospholipid in health and disease. 
Three types of compounds of different origin and structure 
have been reported as PAF antagonists: PAF analogues (e.g. CV-
3988), natural products (e.g. kadsurenone, BN 52021) and 
synthetic compounds (e.g. the hetrazepines brotizolam and WEB 
2086, and 48740-RP).99 The pharmacology of these antagonists is 
basically determined by the pharmacology of PAF. 98 It is to be 
expected that all the effects induced by exogenous PAF can be 
inhibited by such compounds. In addition, PAF involvement in 
animal models of diseases, like endotoxin shock and anaphylaxis, 
can be used for pharmacological characterization of these PAF 
antagonists, which appear to act by occupying PAF binding sites 
(or receptors) on the effector cells. These PAF antagonists 
displace the PAF molecules from receptor-binding sites, in most 
cases without themselves initiating any response. Their action is 
therefore a receptor-mediated process, competitive and 
reversible.99 ,1°0 
3.3 Prostaglandins 
3.3.1 Biosynthesis and action of prostaglandins 
The PGs and related compounds are derived from 20-carbon 
essential fatty acids that contain three-, four or five double 
bonds; 8,11,14-eicosatrienoic acid (dihomo-gamma-linolenic acid), 
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5,8,11,14-eicosatetraenoic acid (arachidonic acid) and 
5,8,11,14,17-eicosapentaenoic acid. 
The chemical structure of PG consists of a cyclopentane ring 
and two alphatic side chains. The synthesis of PGs from fatty 
acids is preceded by the oxygenation and cyclization of the 
pentane ring by cyclooxygenase, leading to an unstable C15-
hydroperoxy-C9-C11-endoperoxide prostaglandin G. Endoperoxides 
which are chemically unstable form the intermediate substrates 
for tissue-specific synthesis of a variety of biologically active 
PGs.lOl They fall into several main classes, designated by 
letters and distinguished by substitutions on the cyclopentane 
ring. The main classes are subdivided in accord with the number 
of double bonds in the side chains. This is indicated by sub-
script 1, 2 or 3 and reflects the fatty acid precursor. Thus, PGs 
derived from 8,11,14-eicosatrienoic acid carry the subscript 1; 
those derived from arachidonic acid carry the subscript 2; and 
those derived from 5,8,11,14,17-eicosapentaenoic acid carry the 
subscript 3. In man arachidonic acid is the most abundant 
precursor and there is little evidence that PGs of the 1 or 3 
series are important. However, PGs of the 3 series have greater 
significance in fish and marine animals where 5,8,11,14,17-
eicosapentaenoic acid is the precursor. 
More than 100 natural PGs, isomers and their metabolites are 
now known. The E- and F-type PGs have been termed primary 
PGs.102,103 They, as well as PGs of the A-, B-, c- and D-types, 
are relatively stable compounds while PGs G, H and I are unstable 
in aqueous media at physiological pH and temperature. 
In inflammation most PGs are powerful vasodilators. By 
promoting blood flow in the inflamed region they enhance edema 
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formation and leukocyte infiltration. 
The pain producing activity of bradykinin and of histamine 
is potentiated by PGs.104 
Nevertheless, the view that the inflammatory process is 
exclusively promoted by prostaglandins is oversimplified. 
Evidence is accumulating that, depending on the experimental 
situation that is studied, PGE2 displays either pro- or anti-
inflammatory effects.105-107 While such a dual function has not 
been convincingly shown for other products of AA-bioconversion, 
the di-homo-gamma-linoleic acid derived PGE1 does share this 
property with PGE2 .106-108 AA and di-homo-gamma-linoleic acid 
are essential fatty acids (EFA) and EFAs per se are reportedly 
either pro- or anti-inflammatory.106,107,109 
While under some conditions PGE can counteract non-immune 
plasma exudation, its anti-inflammatory effects with model 
conditions in which immunecompetent lymphocytes andjor macro-
phages are involved deserve more attention. Besides their 
inflammatory effects,105-107 the E-type prostaglandins have, in 
fact, been proposed as regulators of the immune response.110,111 
In addition, a modulatory involvement in immune reactions has 
also been ascribed to essential fatty acids, albeit the immune-
modulatory effects of EFA are partially mediated through 
conversion to PGE.109 Lymphocytes and macrophages, as pivotal 
targets for both the anti-inflammatory and immunomodulatory 
effects of PGE, form the obvious link between the two 
functions. 107 
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3.3.2 Inhibition of prostaglandin action 
3.3.2.1 Cyclooxygenase inhibitors. 
In 1971 Vane reported that aspirin and indomethacin could 
inhibit prostaglandin biqsynthesis. He showed that this effect 
was exerted directly on the enzymatic conversion of arachidonic 
acid to prostaglandins. These drugs prevent production of the 
prostaglandin endoperoxides by the cyclooxygenase enzyme and as 
a result inhibit the synthesis of all of the products beyond this 
step in the metabolic pathway.112,113 Cyclooxygenase inhibitors 
however promote the secretion of lysosomal enzymes and 
LTB4 .114,115 
3.3.2.2 Prostaglandin antagonists 
Most or all actions of the various prostaglandins are 
exerted through activation of specific receptors.116,117 
Polyphloretin-phosphate possesses prostaglandin-antagonist 
effects and can inhibit signs of ocular inflammation.118 
3.4 Leukotrienes 
3.4.1 Biosynthesis and action of leukotrienes 
The leukotrienes constitute a group of acyclic 20-carbon 
essential fatty acid derivatives. Their name is derived from the 
fact that they were first isolated from leukocytes, and that they 
contain a triene, i.e. three conjugated double bonds. Their 
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numerical subscripts refer to the total number of double bonds, 
whereas the letters refer to the substituents in alphabetic 
order. Thus, all the LTs with the numerical subscript 3 are 
derived from eicosatrienoic acid, those with subscript 4 from 
arachidonic acid and those with subscript 5 from eicosapentaenoic 
acid.119,120 
The LTs are formed primarily from arachidonic acid. The 
leukotrienes LTA4 , LTB4 , LTC4 , LTD4 , LTE4 and LTF4 arise through 
the 5-lipoxygenase pathway from arachidonic acid with as 
intermediate a 5-hydroperoxy-eicosatetraenoic acid (5-HPETE). 
Reaction of LTA4 with gluthathione, a tripeptide, yields LTC4 
which can be further metabolized to respectively LTD4 , LTE4 and 
LTF4 • Metabolism of LTA4 with a hydrolase yields LTB4 . 
Leukotrienes are formed analogously from 5,8,11-eicosa-
trienoic acid (LTB3 , LTC3 , LTD3 and LTE3 ) and from 5,8,11,14,17-
eicosapentaenoic acid (LTB5 , LTC5 , LTD5 and LTE5 ). Leukotrienes 
may also arise through the 12- and 15-lipoxygenase pathways.121 
The LTs exert marked effects in many biological systems. 
Leukotriene B4 is one of the strongest chemotactic agents 
known for leukocytes. It causes aggregation of cells, produces 
superoxide and mobilizes the calcium pool of the cells. LTB5 is 
considerably less chemotactic. 121-124 LTC4 , LTD4 and LTE4 have 
little if any effect on leukocyte chemotaxis. 
LTC4 , LTD4 and LTE4 give marked constriction of coronary 
arteries in a number of species and have a negative inotropic 
effect.125-128 LTc4 and LTD4 contract human broncheal and 
tracheal muscles129,130 and stimulate pulmonary mucus 
secretion.131,132 In the skin erythema and whealing is caused by 
LTC4 , LTD4 and LTE4 and induration by LTB4 .133,134 
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3.4.2 Inhibition of leukotriene action 
3.4.2.1 Enzyme inhibitors 
There are many sites throughout the path of the synthesis of 
LTs where interruption can take place. Of course prevention of 
the release of unsaturated fatty acids will deprive the lipoxy-
genase as well as the cyclooxygenase pathway of substrate. This 
can be done effectively by the use of corticosteroids as has been 
discussed before. 
Many cyclooxygenase inhibitors also inhibit to some extent 
5-lipoxygenase. Examples are acetylsalicylic acid, indomethacin 
and phenylbutazone.135 
Some selective 5-lipoxygenase inhibiting drugs have been 
developed34,136 though none of these have been accepted at this 
stage as a safe and useful clinical drug. 
3.4.2.2 Leukotriene antagonists 
Receptor sites for LTC4-LTD4 have been demonstrated on the 
cell surface of leukocytes. LTC4 and LTD4 receptor antagonists 
have been developed, showing also in vivo activity in various 
animal models. 136 ,137 
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3.5 Cyclic nucleotides 
3.5.1 cyclic nucleotides as second messengers in an eicosanoid 
induced inflammatory response 
When a chemical mediator initiates a metabolic response in 
the cell this is effected through a membrane-linked specific 
receptor causing the formation of an intracellular messenger 
molecule. The intracellular messenger is often called the second 
messenger, which on its turn then stimulates or depresses some 
characteristic biochemical activity in the target cell. The 
intracellular activities of PGs and LTs are dependent on such 
receptor mediated processes.ll6,136-138 The second messengers in 
this case are cyclic nucleotides, such as cyclic adenosine 
monophosphate (cAMP) or cyclic guanidine monophosphate (cGMP). 
Adenosine triphosphate can be metabolized by the enzyme 
adenylcyclase to 3.5 cAMP and free pyrophosphate. The enzyme 
responsible for the destruction of cAMP is phosphodiesterase, 
which catalyzes the hydrolytic reaction by which cAMP is 
converted to adenosine 5'phosphate.l39 
Prostaglandin E and prostacyclin are among the most potent 
stimulators of cAMP generation. Prostaglandin E2 gives rise to an 
activation of adenylcyclase and thereby an increase in the intra-
cellular cAMP level.l40 A rise in cAMP is associated with a 
reduction of lymphocyte stimulation, cell mediated cytotoxicity, 
antibod~ and lymphokine production, in polymorphonuclear leuko-
cytes it accompanies lysosomal-enzyme release.l41 
A reduced capacity of the cyclooxygenase pathway in 
elicited macrophages is accompanied by low intracellular cAMP 
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levels. While products of the cyclooxygenase pathway of 
arachidonic acid metabolism inhibit lymphocyte functions by 
increasing cAMP, the same processes may be enhanced by products 
of the lipoxygenase pathway, possibly by increasing intracellular 
cGMP.142,143 Leukotriene c 4 induces a rapid transient cAMP 
generation which is PG mediated in isolated macrophages.l42 
3.5.2 Pharmacological manipulation of the cyclic nucleotide 
level 
The level of cAMP or cGMP may be influenced by inhibition or 
stimulation of the action of the regulating enzymes adenylcyclase 
or phosphodiesterase. 
Cyclic nucleotide phosphodiesterase activity can be 
inhibited by caffeine and other methylxanthines, cromoglycate and 
many other agents. Activation of cyclic nucleotide phosphodi-
esterase is possible by insuline, imidazole and some other 
agents. 144 
Guanyl cyclase can be activated by o{ 2 adrenergic agonists, 
muscarinic agonists and opiates.l45 It can be inhibited by 
guanidine-triphosphate, other guanine nucleotides and 
fluoride. 146 
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ABSTRACT 
The effect of topical administration of 3-isobu-
tyl-methyl-xanthine (IBMX), a potent phosphodies-
terase inhibitor, was studied on an experimentally 
provoked uveitis in rabbits. 
After presensitization with an intravitreal injec-
tion of human serum albumin (HSA), intravenous 
antigenic challenge induces blood-aqueous barrier 
breakdown and leukocyte infiltration. The effect 
of IBMX on the blood-aqueous barrier was deter-
mined by scoring the severity of the flare in the 
anterior chamber and by determination of the 
levels of ascorbic acid and protein in the 
aqueous~ Treatment with IBMX 1% two times daily, 
significantly inhibited the breakdown of the 
blood-aqueous barrier and the increase in PGE 2 level of the aqueous humor~ There was no effect on 
leukocyte infiltration~ The therapeutic effect of 
IBMX in blood-aqueous barrier protection is compa-
rable with the effect of topical treatment with 
the corticosteroid medrysone~ 
INTRODUCTION 
Immunogenic uveitis in rabbits can be used as a 
model for the evaluation of ocular anti-inflamma-
tory agents (1,2). HSA administered intravitreally 
to the rabbit eye produces ocular inflammatory 
symptoms which are similar to those observed dur-
ing uveitis ( 3). 
Immunogenic uveitis is caused by an immediate 
hypersensitivity reaction of the rabbit eye (4). 
This type of uveitis is caracterized by conjuncti-
val hyperemia, cellular infiltration and a break-
down of the blood-aqueous barrier (1,2,5,6). 
Characteristics of the breakdown of the blood-
aqueous Uarrier are increased protein and de-
creased ascorbic acid level in the aqueous. 
Phosphodiesterase inhibitors such as theophyl-
line, caffeine and IBMX, raise the level of intra-
cellular cyclic adenosine monophosphate (cAMP) by 
preventing the chemical conversion of cAMP to AMP 
by phosphodiesterase {7}. 
The beneficial effects of an elevated intra-cellu-
44 
lar cAMP level on an immediate hypersensitivity 
reaction in vitro and in vivo have been described 
(8,9,10,11). Systemically applied theophylline 
showed, for example, a marked reduction in exudate 
formation and leukocyte migration in a pleural 
immediate hypersensitivity reaction (9). 
On the contrary disruption of the blood-aqueous 
barrier in the eye, induced by paracentesis or 
intravitreal injection of bacterial endotoxins can 
be antagonized by systemic treatment with imida-
zole, an activator of cAMP-phosphodiesterase 
(12,13,14). Systemically administered theophylline 
potentiates the blood-aqueous barrier disruption 
caused by topical application of prostaglandin E2 
(PGE 2 ) to the eye (15). 
These observations in the eye suggest that 
accumulation of intraocular cAMP promotes the 
barrier damage and that cAMP might be the common 
effector of the barrier breakdown, caused by pros-
taglandin as well as by non prostaglandin agents. 
The object of this study is to evaluate the 
action of IBMX as topically given phosphodiester-
ase inhibitor, on immunogenic uveitis. We also 
compared its action with that of the corticoster-
oid medrysone. 
MATERIALS AND METHODS 
Animals 
Chinchilla rabbits (2,0 to 3,0 kg, aged 6 to 8 
months) were kept in our animal facilities with 
free access to water and standard food. 
HSA-induced uveitis 
Ocular sensitization was induced by an intra-
vitreal injection of 30 ~1 of HSA (20% solution, 
CLB, Amsterdam, The Netherlands) in the right eye. 
The left eye was injected with 30 ~1 sterile 
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saline. The injection was performed with a 3D-
gauge needle through the pars plana~ after local 
anaesthesia with tetracaine 2% eye drops. 
The eyes were daily examined with a slitlamp 
for signs of an inflammatory response. The re-
sponse usually took place within 8 to 20 days in 
the HSA injected eyes. Animals that did not re-
spend with this initial inflammatory reaction were 
excluded from further experiments (about 10% of 
the animals). The primary inflammatory response 
was then allowed to subside until the eyes ap-
peared to be normal on biomicroscopy. This took 
approximately 3-6 weeks from the time of injec-
tion. 
After six weeks the animals were challenged in-
travenously with HSA (1 mg/kg}. Within two hours 
sensitized eyes developed an inflammatory response 
which reached a maximum at 24 hours and remained 
constant till 72 hours after the challenge dose. 
This second inflammatory reaction was used for our 
pharmacological experiments. 
Slitlamp examination 
Before commencement of the experiment all animals 
were checked for the signs of any ocular inflamma-
tion by slitlamp examination. The second inflamma-
tory response was observed and graded according to 
Hogan {16) for hyperemia, flare and cells at zero, 
six, 24 and 72 hours after the intravenous chal-
lenge with HSA- The observer did not know which 
treatment the animals received. 
Sampling of aqueous humor 
At 72 hours paracentesis was performed under gen-
eral anaesthesia with hypnormR {fluanison 10 mgjml 
and phentanyl citrate 0,2 mg/ml) 0,75 ml/kg body 
weight. With a 27 gauge needle approximately 200 
~1 aqueous was aspirated. 
The aqueous was analyzed for white cell count, 
protein, ascorbic acid and PGE
2
. 
Assays 
- The total protein concentration of the 
aqueous was determined according to Bradford {17) 
using HSA as standard. 
- Ascorbate was measured in aqueous within 
hr. after aspiration, using a colorimetric test 
45 
set {Boehringer-Mannheim, Mannheim, West Germany}. 
- PGE2 was determined by a Radio Immune Assay 
kit (New England Nuclear, Boston, Mass., USA). 
- The cell counts of the aqueous humor were 
performed with a haemocytometer. 
Drug treatment 
A 1% suspension of IBMX (Fluka AG, Buchs, switzer-
land) was prepared using 0,5% methylcellulose as 
the vehicle. 
A 1% suspension of medrysone in polyvinylalco-
hol 1,4% (HMS liquifilm) was obtained from Aller-
gan {Irvine, CA, USA). The control group 
treated with methylcellulose 0,5%. 
At 16 hours prior to challenge and twice daily 
after challenge, the inflamed eyes were treated 
topically with 30 ~ of either IBMX, medrysone or 
the vehicle (0,5% methylcellulose). 
Statistics 
For protein, ascorbate, PGE 2 and cell count the 
values of the uninflamed left eye were sUbtracted 
from the values of the inflamed right eye. On the 
mean differences of these values statistical anal-
ysis was performed. 
For the Hogan score, analysis was performed on the 
mean values observed in the inflamed eyes. 
Differences between mean values were tested for 
significance with the Student t-test for unpaired 
data. 
RESULTS 
HSA induced anterior uveitis 
Intravenous administration of HSA to animals in-
duced a mild anterior uveitis within two hours, 
that lasted for approximately 14 days in the HSA 
sensitized eye. No posterior synechiae were seen. 
The uveitiS was characterized by hyperemia which 
was maximal at six hours and by aqueous flare and 
aqueous cellular infiltration with a maximum 
after 24 hours (fig. 1, a,b,c). 
In the nonsensitized contralateral eyes no hy-
peremia, aqueous flare or aqueous cellular re-
sponse were noted. 
At 72 hours protein and PGE
2 
levels ln the 
aqueous humor were significantly increased and 
hours ullor llltnli!Cnous challenge dose with HSA 
Fig. 1 
Hogan's score (mean ± SEM) for: 
a) conjunctival &yperemia 
b) flare 
c) cells 
in untreated HSA-induced uveitis, n=9 (0), treated 
with IBMX 1%, n~a (O) or medrysone 1%, n=9 (B). 
* P < 0.05, significance of treated v.s. untreated 
group. 
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ascorbate was decreased in the HSA-sensitized eyes 
in comparison with the non-sensitized contralater-
al eyes (table 1) . 
Sli tlamp examination 
- Conjunctival hyperemia (fig. la) 
Pretreatment with IBMX induced some conjunctival 
hyperemia before the uveitis was provoked by the 
intravenous challenge dose. After medrysone pre-
treatment no hyperemia was observed. 
Conjunctival hyperemia in the medrysone treated 
group was significantly decreased at 6, 24 and 72 
hours compared to the treated group. 
IBMX had no effect on conjunctival hyperemia com-
pared to the placebo group. 
- Aqueous flare {fig. lb) 
Both IBMX and medrysone significantly reduced the 
aqueous flare during the course of the uveitis. 
-Aqueous white blood cells {fig.lc, table 1) 
Hogan's score for white cells was significantly 
diminished at 6, 48 and 72 hours in the medry-
sone treated group and in the IBMX treated group 
at 48 hours. 
The cell count at 72 hours was significantly 
reduced in the medrysone treated group but not in 
the IBMX treated group {table 1). 
Composition of aqueous humor 
- Protein 
IBMX and medrysone both significantly inhibited 
the increase in protein content of the aqueous at 
72 hours. 
- Ascorbate 
IBMX and medrysone both significantly inhibited 
a decrease in ascorbic acid content of the 
aqueous at 72 hours. 
- PGE
2 
IBMX but not medrysone significantly inhibited the 
production of PGE 2 in the aqueous at 72 hours. 
DISCUSSION 
The results indicate that IBMX and the steroid 
medrysone are effective inhibitors of several 
inflammatory responses in the HSA-induced immune 
complex uveitis. 
Medrysone reduced Hogan's score for conjuncti-
val hyperemia, flare and aqueous cells. In the 
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TABLE 1 
MEAN DIFFERENCES FOR PROTEIN, ASCORBATE, PGE2 AND CELL COUNT IN THE AQUEOUS BETWEEN HSA-INDUCED UVEITIS 
EYES WITH AND WITHOUT TREATMENT AND THE UNINFLAMEO CONTRALATERAL EYES AT 72 HOURS. 
Protein (g/1) 
OD-OS 
Ascorbate (mg/1) PGE2 (pg/ml) Cell count (10
4 /m1) 
00-0S 
Non treated HSA eyes ( n=9} 
IBMX treated HSA eyes (n=S) 
Medrysone treated HSA eyes 
(n=9) 
3.3 0. 7 
1.6 ± 0.6* 
1.5 ± 0.4* 
oo-os 
-56.0 ± 
-4.1 ± 
-14.0 ± 
00-0S 
13.7 146 ± 61 16.4 5. 7 
2.7*** 11 6*** 10.6 ± 6.4 
5.5** 130 ± 16 2.1 ± 1.5* 
Values represent the differences between the levels of inflamed eyes (OD) and uninflamed eyes (OS). 
All values are mean ± SEM. 
Mean protein and ascorbate values in uninflamed eyes (n=26}, were 0,5 g/1 and 181 mg/1. In the uninflamed 
eyes PGE was below detection limit (< 25 pg/ml), and cells were not present. Signific~nce of difference v.s. control: * P < 0.05; ** P ( 0.01; *** P < 0.001. 
aqueous of medrysone treated rabbits obtained 72 
hours after the challenge dose, there was a de-
creased level of protein, an increased level of 
ascorbic acid, and a reduced cell count in com-
parison to vehicle treated animals. No change was 
observed in the levels of PGE2 . IBMX reduced Ho-
gan's score for aqueous cells at some time points 
and reduced flare during the whole course of the 
inflammation. There was no effect on hyperemia, 
but this observation was hindered by the fact that 
in a normal non-inflamed rabbit eye some ( 1+ in 
Hogan's score) hyperemia was produced by topical 
treatment with IBMX. 
At 72 hours IBMX reduced the increase of protein. 
the decrease of ascorbic acid, and the increase 
of PGE2 , but not the aqueous cell count as com-
pared to the non-treated inflamed eyes of the 
controls. 
Medrysone protects the eye against blood-
aqueous barrier disruption as well as cellular 
infiltration in immunogenic uveitis. IBMX only 
protects the blood-aqueous barrier but has no 
significant effect op cellular infiltration. 
The mechanism of action of corticosteroids is 
explained by the induced synthesis of lipocortins 
specific proteins, that are inhibitors of phospho-
lipase A2 (18). In this way the amount of arachi-
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donie acid available as a substrate for the cycle-
oxygenase and lipoxygenase pathway is diminished, 
which may reduce the production of prostaglandins 
respectively leukotrienes. The mechanism of phos-
phodiesterase inhibitors in inflammation is ex-
plained by the intracellular elevation of cAMP, 
which reduces the production of PGE2 in an immedi-
ate hypersensitive reaction (9) and the release of 
lysosomal enzymes in leukocytes at the site of the 
inflammation (8,10,19). Topical treatment with 
theophylline reportedly had no effect on blood-
aqueous barrier breakdown caused by PGE
2 
and sys-
temic treatment increases the blood-aqueous bar-
rier disruption in an inflammatory response which 
was not accompanied by cellular infiltration (15). 
These observations of the above study were not 
confirmed in our experiments using IBMX as inhibi-
tor of phosphodiesterase. However, IBMX is 15 
times more potent than theophylline as inhibitor 
of phosphodiesterase {7) and our model is differ-
ent in respect of infiltration with leukocytes. It 
is conceivable that IBMX decreases the production 
of prostaglandins in these leukocytes and that by 
this way the blood-aqueous barrier is protected in 
our model. 
Therefore our conclusion is that although in-
traocular cAMP may cause blood-aqueous barrier 
damage, in HSA-induced uveitis in rabbits topical 
IBMX, probably by elevation of intracellular cAMP 
levels, markedly supresses a leukocyte-mediated 
damage of the barrier. 
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ABSTRACT 
Intrastromal injection with human serum albumin 
(HSA) in the rabbit cornea induced edema and a 
ring-shaped leukocyte infiltrate followed by nee-
vascularization. 
The effect of topically administered lipoxygenase 
and cyclooxygenase inhibitors on this inflammatory 
keratitis was studied. 
The lipoxygenase inhibitors Bay 08276 and Rev 5901 
and the cyclooxygenase inhibitor suprofen were 
given as 1% eye drops three times daily during the 
experiment. In eyes treated with lipoxygenase 
inhibitors leukocyte infiltration, neovasculariza-
tion and edema formation decreased. In eyes 
treated with a cyclooxygenase inhibitor the period 
of neovascularization was slightly shortened and 
corneal edema decreased. No influence on leukocyte 
infiltration was seen. 
INTRODUCTION 
Prostaglandins and leukotrienes play an important 
role in inflammation ( 1, 2). 
These inflammatory mediators are derived mainly 
from the fatty acid arachidonic acid. This precur-
sor fatty acid is stored as component of the phos-
pholipids in cell membranes and is released en-
zymatically by phospholipase A2 following a vari-
ety of stimuli (3). Arachidonic acid is rapidly 
oxygenated either by a cyclooxygenase to prosta-
glandins (PGs) or by a lipoxygenase to leuko-
trienes (LTs). In general prostaglandins con-
tribute to the formation of edema and erythema 
( 4). Leukotriene C4 leukotriene 
may cause vascoconstriction followed 
capillary leakage and edema (5), while leukotriene 
B4 (LTB4 ) is a potent chemotactic agent which 
plays a role in the recruitment of leukocytes into 
the site of inflammation (6). 
Steroidal anti-inflammatory agents inhibit the 
release of arachidonic acid by indirect inhibition 
of phospholipase A2-activity (7). In this way by 
depriving the cyclooxygenase as well as the lip-
49 
oxygenase pathway of their substrate these agents 
are effective as anti-inflammatory drugs (fig. 1). 
The mechanism of action depends on binding of the 
steroid to a cycloplasmic receptor and transloca-
tion of this complex to the nucleus where it 
induces the synthesis of a protein whi th anti-
phospholipase properties. Several of these pro-
teins gave been described and they have been named 
lipocortins (8). Current non-steroidal anti-in-
flammatory drugs like indomethacin or suprofen are 
inhibitors of cyclooxygenase preventing the for-
mat ion of prostaglandins ( 1, 9). Recently compounds 
have been developed which selectively inhibit 
lipoxygenase, preventing formation of leukotrienes 
(2,10,11). These lipoxygenase inhibitors could 
have, either alone or in combination with a cycle-
oxygenase inhibitor, a significant effect in 
treatment of non-infective inflammatory disorders 
(fig. 1). 
The role of prostaglandins and leukotrienes as 
mediators in the ocular inflammatory response in 
general and of the cornea in particular has been 
Phospholipids 
l 
r 
phospholipase A2 
Fig. 1 Schematic representation of the arachidonic 
acid pathway to inflammatory mediators and 
interference with the used lipoxygenase and 
cyclooxygenase inhibitors in this pathway. 
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described ( 12-15). Arachidonic acid can be metabo-
lized by the cornea to products of cyclooxygenase 
and lipoxygenase (16-18). The stimulatory effect 
of LTB4 on leukocyte infiltration in the eye has 
been observed ( 14,15, 19). Prostaglandins are known 
as potent mediators in the development of corneal 
neovascularization ( 16, 20). 
Topically administered corticosteroids are the 
most potent drugs for suppression of corneal in-
flammatory symptoms. Corticosteroids however have 
an array of side effects on the eye. Their ability 
to elevate intraocular pressure, inhibit wound 
healing, facilitate the growth of fungi and en-
hance herpes simplex virus replication has been 
reported (21-25). The reports on the effect of 
cyclooxygenase inhibiting drugs on corneal in-
flammation are contradictory. Stimulation as well 
as suppression of corneal inflammatory symptoms 
have been reported (26-32}. Lipoxygenase inhibi-
ting compounds have not been tested on this model 
although reports on the use of lipoxygenase in-
hibiting drugs on corneal transplantation, epithe-
lial wound healing and immune complex uveitis have 
appeared ( 16,33, 34). 
A delayed hypersensitivity reaction of the 
rabbit cornea can be used as a model for testing 
anti-inflammatory properties of drugs (26-31}. In 
this animal model the intrastromal injection of 
antigen induces an annular zone of antigen-anti-
body precipitate (35,36-39,40) which provokes an 
opaque ring in the cornea consisting mainly of 
infiltrate of polymorphonuclear leukocytes. Here-
after neovascularization starts from the limbus 
(3,35,36). Manifestations of an immediate hyper-
sensitivity reaction in the cornea in man are 
among others; a marginal ulcus in the course of 
microbi-allergic keratitis, a corneal ulcus in the 
course of periarteritis nodosa and herpes simplex 
accompanied disciform keratitis (37). 
Because leukocyte infiltration plays a major role 
in this type of corneal disease the treatment with 
lipoxygenase inhibitors is of interest. These 
inhibitors are supposed to prevent LTB4 formation 
and thereby chemotaxis of polymorphonuclear leuko-
cytes in the cornea. 
50 
Leukocyte infiltration has been regarded by 
some authors as a prerequisite of corneal edema 
and neovascularization (36,41,42). Therefore these 
symptoms might also be influenced by the use of 
lipoxygenase inhibitors. 
The purpose of our present report was to com-
pare the anti-inflammatory effects of two selected 
lipoxygenase inhibitors, a corticosteroid and a 
cyclooxygenase inhibitor. 
MATERIALS AND METHODS 
~ 
The experiments were performed in male pigmented 
chinchilla rabbits weighing 2.0-2.5 kg. All eyes 
were initially examined with a slit lamp. Only 
animals without any sign of ocular inflammation 
were included in the study. Each pharmacological 
trial consisted of 8 animals. The vehicle treated 
control group consisted of 16 animals. 
Immunization 
Immunization of the pigmented rabbits was per-
formed by injection of 20 1 pyrogen free human 
serum albumin (HSA) (20% solution, C~L-B., Amster-
dam, The Netherlands) into the cornea of both 
eyes, according to Morawiecki (43), after corneal 
anaesthesia with 0.4% oxybuprocaine and sedation 
by intramuscular injection (0,75 ml/kg body 
weight) of Hypnorm~ containing fluanison 10 mg and 
phentanyl citrate 0. 2 mg per ml. 
Drug treatment 
Rabbit eyes were treated with Bay 08276 {N-1,2,4 
triazol-3-1-p-chloropheny lsulfamide, Bayer AG, 
Wuppertal, Germany), Rev 5901: {a-pentyl-3-2-
quinolinyl-methoxy)-benzenemethanol, {Revlon 
Health Care, Tuckahoe, N.Y., U.S.A.) and Suprofen 
(Alcon, Fort Worth, Texas, U.S.A.) {fig. 2). 
Because all drugs used in this study were badly 
solvable in water they were applied as suspension 
in hydroxypropylmethylcellulose eye drops as 
vehicle, composed of 0,5% hydroxypropylmethylcel-
lulose and 0,9% NaCl in water, freshly prepared 
every four days. To have some idea about the 
relative potency of these experimental drugs all 
were prepared as 1% suspensions. Fluorometholone 
0,1~ in 1,4% polyvinylalcohol (Allergan, Irvine, 
~ OH 0~ N I 
~ REV 5901 cH, 
" / 
COOH CH H ¢ ()-NH-S-oCI 
uco 
suprofen BAY 0 8276 
Fig. 2 Structural formulas of the lipoxygenase and 
cyclooxygenase inhibitors used in treating 
immunogenic keratitis. 
CA, U.S.A.) was used as a positive control. 
Controls were treated with 0,5% hydroxypropyl-
methylcellulose in 0,9% NaCl only. 
Treatment with the above mentioned preparations, 
one drop three times a day instilled into the 
conjunctival sac, was started eight days after 
immunization and continued for the duration of the 
experiments. 
Parameters of ocular inflammation 
The keratitis of the rabbit eye was evaluated by 
measuring corneal edema formation, neovasculariza-
tion and the occurrence of Wesseley's phenomenon 
in the cornea. This white corneal ring is composed 
of precipitated antigen-antibody complexes and in-
flammatory cells (35,38,41,43). These three para-
meters of corneal inflammation can be well ob-
served in vivo. The clinical observation was orga-
nized in a masked fashion and for each animal the 
values of both eyes were averaged. 
Corneal aspect: 
We counted the number of days during which opaque 
rings or a diffuse completely opaque cornea was 
visible as well as the number of days on which 
vessels were present in the cornea. 
Pachymetry: 
A Haag-Streit slit lamp with a pachymeter fitted 
with central fixation lights according to Mishima 
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and Hedbys { 44) was used for measurements of 
corneal thickness {36). From each eye the mean of 
three measurements was taken. 
central corneal thickness was measured before and 
at the 7, 9, 11, 14, 16, 18, 20, 23 and 27th day 
after intrastromal injection with HSA. 
For each animal the differences between the pachy-
metry measurements before and after intraocular 
injection with HSA were recorded as !::. corneal 
thickness or edema formation. 
For each animal separately D. corneal thickness was 
plotted in time and from these graphs the area 
under the curve was measured. Area under the curve 
was calculated using the trapezoideal rule between 
zero time and 2 7 days. 
Statistical analysis 
Data were analyzed by non-parametric methods to 
avoid assumptions about the distribution of the 
variables involved. 
Wilcoxon's signed rank test was applied for the 
mean pachymetry data obtained at several time 
points in the treated and untreated groups during 
the period of inflammation and the Mann-Whitney u-
test served for analysis of the duration of neo-
vascularization and corneal opacification in the 
treated and the untreated eyes at any given time. 
Significance of difference is given for two-tailed 
observations, P values < 0. 05 were regarded as 
significant. 
RESULTS 
Non-treated eyes 
The corneas treated only with hydroxypropylmethyl-
cellulose showed, seven to ten days after 
injection of HSA, clouding starting at the limbus 
as well as formation of wesseley's ring on about 
day 14-17. 
This ring remained present for one to eight days. 
Two to four days after the ring became visible, 
vascularization of the cornea started over 360° 
from the limbus towards the center, progressed 
till about day 22-25 and then regressed quickly 
resulting in all cases in a clear cornea 30 Gays 
after the injection of the HSA. 
All animals injected with HSA responded with this 
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0.50 
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_____. REV 5901 
0.30 
0.20 
0.10 
0.00 
7 11 14 16 18 20 23 27 
start treatment days after intracorneal injection with HSA ---.. 
Fig. 3 Comparison of changes in corneal thickness 
during immunogenic keratitis treated with 
the lipoxygenase inhibitors Bay 08276 
(n=8), Rev 5901 (n=8) and a vehicle treated 
control group (n=l6). Mean 11 corneal 
thickness was calculated from the differ-
ence between the pachymetric measurements 
before intraocular injection with HSA and 
any given time thereafter (mean ± SEM). 
ring formation and neovascularization. Corneal 
edema formation recorded with pachymetry started 
around day seven and lasted till day 30 (fig. 3, 
4). 
Treatment with corticosteroid 
None of the six rabbits treated with fluorometho-
lone 0,1% eye drops developed any visible sign of 
infiltration or neovascularization. There was no 
difference in corneal thickness of these eyes 
compared to non-inflamed eyes {not shown) -
Treatment with lipoxygenase inhibitors 
In the eight rabbits treated with Bay 08276 or Rev 
5901 the period of corneal opacification was 
shorter in comparison with the controls. Wesse-
ley's ring in the treated group was frequently 
incomplete, and corneal opacification was less 
intense. Vessel growth was significantly dimin-
ished (table 1). we noted a marked inhibition of 
corneal edema with Bay 08276 treatment, and a less 
strong inhibition in Rev 5901 treated animals 
(table 1, fig. 3). 
Treatment with a cyclooxygenase inhibitor 
In eight rabbits treated with suprofen the period 
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0.50 
0.40 
0.30 
0.20 
0.10 
0.00 
Fig. 
o-----o controls 
---------- Suprofen + BAY 08276 
a---. Suprofen 
7 9 11 14 16 18 20 23 27 
start treatment days after intracorneal injection with HSA ____.. 
4 Comparison of changes in corneal thickness 
during immunogenic keratitis treated with 
the cyclooxygenase inhibitor suprofen 
(n=8), combined treatment with Bay 08276 
and suprofen (n=8) and a vehicle treated 
control group (n•l6). Mean b. corneal thick-
ness was calculated from the difference 
between the pachymetric measurements before 
intraocular injection with HSA and any 
given time thereafter (mean ± SEM). 
of corneal opacification was not significantly 
shortened. The period of vessel growth was signi-
ficantly shortened. Also a marked inhibition of 
corneal edema in suprof en treated animals was 
noted (table 1, fig. 4). 
Combined treatment with a lipoxygenase and a cy-
clooxygenase inhibitor 
The eight rabbits treated with a combination of 
Bay 08276 and suprofen showed a shorter period of 
corneal opacification and vessel growth than the 
controls {table 1). 
Also a strong inhibition of corneal edema with 
combined treatment was noted (table 1, fig. 4). 
There was no significant difference between the 
effect of combined treatment with Bay 08276 and 
suprofen as compared to treatment with the lipoxy-
genase inhibitor Bay 08276 alone. 
DISCUSSION 
Animals treated only with the hydroxypropylmethyl-
cellulose vehicle in this study responded for 100% 
with corneal opacification, neovascularization and 
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TABLE 1 
CORNEAL OPACITY, GROWTH AND EDEMA FORMATION DURING IMMUNOGENIC KERATITIS 
Controls (n=16) 
Bay 08276 1% (n=8) 
Rev 5901 1% (n=8) 
Supra fen 1% (n=S) 
Bay 08276 1% + 
Suprofen 1% (n=8) 
Duration of corneal 
opacity (days) o 
6. 7 ± 0. 5 (3-12) 
1. 3 ± 0,5** (0-5,5) 
3,4 ± 0,6** ( 1-6) 
4,8 1,3 (0-8) 
1,1 ± 0,3** (0-2,5) 
Duration of corneal 
neovascularization 
(days)" 
7,2 ± 0,8 (1-12) 
2,1 ± 0, 7** (0-3) 
2,4 ± 0,8** ( 0-6.5) 
4,0 0,9* (0-7,5) 
1, 9 ± 0,7** ( 0-5.5) 
Pachymetry 
AUC (% compared to 
controls)o 
100 ± 13 2-183) 
27 8* 2- 77) 
36 ± 8* 6- 71) 
32 ± 9* (11- 93) 
23 ± 6* ( 0- 58) 
: mean ± SEM (range); n : number of animals; AUC: area under the curve. 
Significance of difference vs controls for duration of corneal opacity and vessel growth was 
calculated with the Mann-Whitney U test. 
Mean pachymetry values of controls and treated animals at various time points during the 
inflammation were tested for significance of difference with Wilcoxon's signed rank test. 
p < 0,01 
p < 0,002 
edema. The appearence of opaque rings and neovas-
cularization in the cornea is in accordance with 
previous observations using this model of corneal 
anaphylaxis (27,31,35,45). Histology has shown 
that the opaque ring consisted mainly of a poly-
morphonuclear leukocyte infiltrate (31,36). 
The difference in response rate to the antigen of 
the present experiments with previous work on this 
model must be due to the greater sensitivity of 
chinchilla rabbits compared to Dutch blue belts 
(31). This is in accordance with observations made 
by Sery ( 45). 
The suppressive effect of a local corticosteroid 
used as a positive control on the model of immune-
genic keratitis confirms earlier observations 
using this model (31,34). The lipoxygenase inhibi-
tors Bay 08276 and Rev 5901 were both effective in 
the inhibition of leukocyte infiltration, neovas-
cularization and corneal edema. Bay 08276 was the 
most potent one of the two. This drug is also 
effective in the prevention of neovascularization 
and leukocyte infiltration in experimental corneal 
transplants and alkaline burns (16). The cyclooxy-
genase inhibitor suprofen has a limited effect on 
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TABLE 2 
SELECTIVITY OF LIPOXYGENASE AND CYCLOOXYGENASE 
INHIBITORS IN WHOLE CELL ASSAYS IN VITRO* 
Compound Eicosanoid generation 
LTB
4 PGE2 
Bay 08276 10 100 
Rev 5901 n.d. 
Indomethacin n.d. 0, 3 
Suprofen n.d. 0,2 
* Calculated after data given by Todd, Jardin et al. 
and McMillan et al. (9,10,49) Values represent rc 50 ( )-11). (n.d. = not determined). 
corneal neovascularization, but corneal edema was 
strongly inhibited by suprofen. 
Because we counted the number of days corneal 
opacification was visible and not the number of 
leukocytes involved, we could have underestimated 
the effect of lipoxygenase and cyclooxygenase 
inhibitors in this model of corneal disease. Our 
impression was that the number of days on which 
corneal opacification occurred were directly pro-
portional to the size of the area of opacifi-
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cation~ The same was observed for the duration of 
corneal neovascularization. 
Efficacy of inhibition of LTB4 by Bay 08276 and 
Rev 5901 appears to coincide with inhibition of 
corneal opacity and thus of leukocyte infiltration 
and neovascularization. Less inhibition of edema 
by Rev 5901 as compared to Bay 08276 may b~ re-
lated to absence of any effect on PG formation, 
whereas Bay 08276 is less specific and may also 
inhibit PG formation. Suprofen as inhibitor of PG 
and not of LTB4 formation only effects edema for-
mation efficiently and has little effect on neo-
vascularization and no influence on carnal opacity 
(table 2). 
Chemotactic factors produced at the site of the 
antigen-antibody precipitate attract leukocytes. 
The invaded leukocytes on their turn will produce 
prostaglandins and chemotactic leukotrienes and 
this will result in even more leukocytes, infil-
tration by leukocytes, 
edema. 
neovascularization and 
A review of several experimental models of 
corneal neovascularization has revealed that a 
cellular inflammatory reaction occurs in most of 
them prior to neovascularization (36). This sug-
gests that polymorphonuclear leukocytes directly 
or indirectly may provoke corneal vascularization. 
Eliason (46) however found that in the absence of 
invading leukocytes an injured cornea is also 
capable of producing an angiogenic factor from its 
own native elements. The most important stimuli 
for neovascularization have been determined to be 
PGE1 and PGE2 ( 16,10). The efficacy of specific 
lipoxygenase inhibitors in the prevention of nee-
vascularization by blocking LT formation suggests 
that infiltrated leukocytes play a major part in 
the occurrence of this symptom. Perhaps polymor-
phonuclear leukocytes are not necessary for the 
process of neovascularization, but they seem ei-
ther to produce prostaglandins or other angiogenic 
factors of their own or to enhance the production 
water content in normal animals compared to 
neutropenic animals after induction of corneal 
inflammation by intracorneal injection of chemo-
tactic agents. He concluded that the edema for-
mation is due to the elaboration and release of 
certain polymorphonuclear leukocyte products with-
in the cornea. 
Post surgical cornea edema has been reported to be 
reduced after systemic administration of the cy-
clooxygenase inhibitor naproxenR (47). 
In our experiments treatment with the cyclooxyge-
nase inhibitor suprofen resulted in an almost 
complete absence of corneal edema, despite the 
presence of leukocyte infiltrate and neovasculari-
zation. This suggests, prostaglandin production 
must play a very important role in the development 
of corneal edema. The effect of lipoxygenase inhi-
biters on corneal edema is probably due to preven-
tion of the positive feedback phenomenon in leuko-
cyte infiltration as described above. 
The effect of cyclooxygenase inhibiting drugs 
on corneal inflammatory symptoms is controversial. 
Indomethacin has been reported to have a sup-
pressive effect on corneal neovascularization (28-
30,48) and suprofen on polymorphonuclear leukocyte 
accumulation (32). Other investigators have found 
a stimulation of polymorphonuclear leukocyte accu-
mulation ( 27,31). 
Our conclusion is that the lipoxygenase inhibi-
tors we used, have a strong inhibiting influence 
on symptoms of corneal inflammation. In view of 
the known undesirable side effects of steroid 
these drugs may be of interest as topical ophthal-
mic preparations. 
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of these substances in corneal tissue. CORRESPONDING AUTHOR 
Corneal edema is frequently observed in asso-
ciation with corneal inflammation. Chusid (42) 
demonstrated a significant increase in corneal 
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ABSTRACT 
Several unsaturated fatty acids are precursors of 
prostaglandins and leukotrienes. Depending on 
their precursor, these prostaglandins and leuko-
trienes have different biological characteristics. 
The effects of topically administered fatty acids 
on an experimentally provoked inflammatory kerati-
tis were studied in rabbits . Intrastromal injec-
tion with human serum albumin induced in the cor-
nea a ring-shaped infiltration with leukocytes, 
corneal edema and neovascularization. 
Arachidonic, y-lin?lenic, dihomo-y-linolenic 
{DHGL), eicosapentaenoic (EPA) and columbinic acid 
were given as eye drops in a suspension in 
hydroxypropylmethylcellulose 0.5% three times 
daily during the experiment. EPA, DHGL, columbi-
nic, and y-linolenic, but not arachidonic acid, 
showed a significant inhibition of either leuko-
cyte infiltration, edema or neovascularization. 
The inhibitory effects of these fatty acids may be 
caused by topical inhibition of the formation of 
prostaglandins and leukotrienes in the arachidonic 
acid cascade in the rabbit cornea. 
INTRODUCTION 
The arachidonic acid cascade is the sequence of 
events taking place in a tissue when cell mem-
branes, triggered by mechanical, physical or chem-
ical trauma or immune complex deposition, produce 
the fatty acid arachidonic acid in a kind of 
autolytic process where the phospholipids of cell 
membranes are attacked by the enzyme phospholipase 
Arachidonic acid on its turn can be converted 
by two different ways to prostaglandins or leuko-
trienes. In ocular inflammation prostaglandins are 
produced by the enzyme cyclooxygenase and leuko-
trienes by the enzyme lipoxygenase (1-6). 
The prostaglandins are responsible for inflammato-
ry signs such as vasodilatation and tissue swel-
ling by edema formation (7,8). The leukotrienes 
are involved in leukocyte infiltration by chemo-
taxis (9-12). 
57 
The aim of our study was to intervene in the 
inflammatory response of the rabbit cornea through 
possible inhibition of the production of prosta-
glandins and leukotrienes by topical application 
of various unsaturated fatty acids. 
MATERIALS AND METHODS 
Animals 
The experiments were performed in male pig-
mented chinchilla rabbits weighing 2.0-2.5 kg. All 
eyes were initially examined with a slit lamp. 
Only animals without any sign of ocular inflamma-
tion were included in the study. Each pharmacolog-
ical trial consisted of 8 animals. The vehicle 
treated control group consisted of 16 animals. 
Immunization 
Immunization of the pigmented rabbits was per-
formed by injection of 20 ~1 pyrogen free human 
serum albumin (HSA, 20% solution, C.L.B._, Amster-
dam, The Netherlands) into the cornea of both 
eyes, according to Morawiecki (13), after corneal 
anaesthesia with 0.4% oxybuprocaine and sedation 
by intramuscular injection (0,75 ml/kg body 
weight) of HypnormR containing fluanison 10 mg and 
phentanyl citrate 0.2 mg per ml. 
Drug treatment 
EPA, DHGL, y-linolenic acid and arachidonic 
acid were obtained from Sigma (St. Louis, MO, 
USA). Columbinic acid was a gift from Dr. Houts-
muller (Unilever Research Laboratories, Vlaarding-
en, The Netherlands). The fatty acids were stored 
in the dark under nitrogen to prevent oxidation. 
Fatty aCid suspensions in concentrations of 3% 
for columbinic acid and 1 % for EPA, DHGL, y-
linolenic and arachidonic acid, were prepared with 
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0, 5% hydroxypropylmethylcellulose in phosphate 
buffered saline (pH 7.4) as vehicle. 
Both eyes of rabbits were treated with a fatty 
acid preparation, one drop of 30 ~1 three times 
daily instilled unto the conjunctival sac. Treat-
ment was started eight days after immunization and 
continued for the duration of the experiment. 
Controls were treated with the vehicle only. 
Parameters of ocular inflammation 
Keratitis of the rabbit eye was evaluated by 
measuring corneal edema formation, neovasculariza-
tion and the occurrance of the annular leukocyte 
infiltrate in the cornea {Wesseley's ring) (14). 
These three parameters of corneal inflammation can 
be well observed in vivo. The clinical observation 
was organized in a masked fashion and for each 
animal ~he values of both eyes were averaged. 
Corneal aspect: 
The number of days were recorded during which 
an opaque corneal ring or a completely opaque 
cornea was visible as well as the number of days 
on which growth of vessels into the cornea was 
visible. 
Pachymetry: 
A Haag-Streit slit lamp with a pachymeter fit-
ted with central fixation lights according to 
Mishima and Hedbys (15) was used for measurements 
of corneal thickness. From each eye the mean of 
three measurements was taken. Central corneal 
thickness was measured before and at regular time 
intervals after intrastromal injection with HSA. 
For each animal the differences between the 
pachymetry measurements before and after intraocu-
lar injection with HSA were recorded as A corneal 
thickness or corneal edema. For each animal sepa-
rately A corneal thickness was plotted against 
time and from these graphs the area under the 
curve was calculated using the trapezoideal rule 
between zero time and 27 days. 
Determination of fatty acids in lipids of corneal 
tissue after topical treatment with eicosapentae-
noic acid or columbinic acid 
Three groups of four rabbits with normal eyes 
received during four days a treatment with either 
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the vehicle or a suspension of 3% columbinic acid 
or 1% EPA. Rabbits were sacrificied using an over-
dose of penthothal on the fifth day four hours 
after they received the last dose of the eye 
drops. Using a 14 mm trephane the corneas were 
dissected from the intact enucleated eye. The 
corneas were washed four times in saline to pre-
vent contamination in the analytical procedure 
with topically applied fatty acids. In each of the 
three groups of animals right and left corneas 
were pooled separately for fatty acid analysis. 
One volume of methanol was added to the pooled 
samples and they were stored at -60°C till bio-
chemical analysis. Lipids were extracted from the 
corneal tissues with a mixture of chloroform: 
methanol (2:1). The chloroform layer was concen-
trated with a stream of nitrogen and the residue 
was transesterified with methanolic hydrochloric 
acid (2h, 65°C). After extraction with a mixture 
of hexane/diethyl ether 50/50 and evaporation of 
the solvent with a stream of nitrogen, the fatty 
acid esters were chromatographed over silica 
columns with hexane/diethyl ether 90/10. 
The fatty acid methyl esters were analyzed with 
gas liquid chromatography after removal of the 
solvent with a stream of nitrogen. A HP 5880 Gas 
Chromatograph equipped with an automatic sampler 
(7672 A, Hewlett-Packard) and a FID detector em-
playing a WCOT glass capillary column (CP SIL 88, 
= 25 em, i.d. ~ 0.22) were used; injection 
temperature 225°C, detection at 350°C, programmed 
from ll0°C to 186°C with 2°C/min. and 10 min. hold 
at the final temperature. 
St~tistical analysis 
Data were analyzed by non-parametric methods to 
avoid assumptions about the distribution of the 
variables involved. 
Wilcoxon's signed-rank test was applied for the 
mean pachymetry data obtained at several time 
points in the treated and untreated groups during 
the period of inflammation and the Mann-Whitney U-
test served for analysis of the duration of neo-
vascularization and corneal opacification in the 
treated and untreated eyes at any given time. 
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Fig. 1 
Changes in corneal thickness during immunogenic 
keratitis in rabbits {controls; n=l6). Eyes were 
treated topically with suspensions of 
(A) columbinic acid 3% (n=8; P < 0.01) 
Significance of difference is given for two tailed 
observations, P values < 0.05 were regarded as 
significant. 
On the data of the fatty acid analysis no 
statistical analysis was performed. 
RESULTS 
Non-treated eyes 
The appearence of keratitis in vehicle treated 
eyes was as follows. One week to ten days after 
intracorneal injection of HSA, clouding of the 
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(B) EPA 1% (nc8; P < 0.01); y-linolenic acid 
(n=8; P < 0.01) 
(C) DHGL 1% (n~S; P < 0.01); arachidonic acid 
(n•8; n.s.). 
P denotes significance of difference vs. controls; 
n ~ number of animals; n.s. = not significant. 
cornea started at the limbus and on about day 14-
17 a white ring of opacification known as Wes-
seley's ring ( 13) appeared. 
The ring was present for one to eight days. 
Within an interval of two to four days vasculari-
zation of the cornea started from the limbus, 
progressed till about day 22-25 and then regressed 
quickly resulting in all cases in a clear cornea 
30 days after the injection of the HSA. 
All animals injected with HSA responded with 
white ring formation and neovascularization. Cor-
neal edema formation recorded with pachymetry 
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- 16 : 0 palmitic 
18 : 0 stearic 
n-3 series n-6 series n-9 series 
t;g Desaturation 
18:3 a- linolenic 18:2 
l>6 Desaturation 
18:4 18: 3 
Elongation ~ ~ 
20: 4 20:3 
' l>5 Desaturation 
• 20: 5 eicosapentaenoic 20:4 
Elongation 
22: 5 22:4 
' ' l>4 Desaturation 
• • 22: 6 docosahexaenoic 22: 5 
Fig. 2 
Schematic representation of three families of 
unsaturated fatty acids. The place of the first 
double bound is designated by n. First number of 
the fatty acid designates chain length, second 
started around day seven and lasted till day 30 
(fig. 1). 
Treatment with fatty acids 
In rabbits treated with EPA, columbinic acid, 
DHGL and y-linolenic acid the period of corneal 
opacification was significantly shorter in compar-
ison with the controls. Vessel growth was signifi-
cantly diminished after treatment with EPA, colum-
binic acid andy-linolenic acid (table I). These 
substances and DHGL also significantly inhibited 
corneal edema formation {Fig. 1, table I). 
Topical application of arachidonic acid neither 
increased nor decreased the inflammatory response 
(table I, fig. lc). 
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linoleic 18: 1 oleic 
r- linolenic 18: 2 
~ 
dihomo- }'-linolenic 20: 2 
arachidonic 20: 3 
~ 
adrenic 22:3 
' t 
22:4 
number after : the number of double bonds of the 
fatty acid. The sequential reactions are indicated 
with bold arrows for the elongation reactions and 
dashed arrows for the desaturation reactions cata-
lyzed by the ~ 9,6,5 and 4 desaturase enzymes. 
Fatty acids in lipids of corneal tissue after 
topical treatment with eicosapentaenoic acid or 
columbinic acid (Table II) 
After four days of topical treatment, EPA 
treated animals showed the occurrence of 1,8% EPA 
(20:5 n-3) and 2.5% of its metabolite (22:5 n-3) 
in the corneal phospholipids. Columbinic acid 
treated animals showed the occurrence of 5,6% of 
this fatty acid in the corneal phospholipids. 
The level of arachidonic acid (20:4, n-6) after 
treatment with both EPA and columbinic acid, de-
creased to 5,9% and 4,9% respectively in compari-
son to the level of 7,5% of arachidonic acid in 
the controls. Also the level of its metabolite 
TABLE I 
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CORNEAL OPACITY, GROWTH OF VESSELS AND EDEMA FORMATION DURING IMMUNOGENIC KERATITIS 
Duration of corneal Duration of corneal Pachymetry 
opacity (days) o Neovascularization AUC ( % compared to 
controls) o 
Controls (n=16) 
Columbinic acid 3% 
(18,2 n-6trans) (n=8) 
6,7 ± 0,5 
3,7 ± 0,7***(2-5,5) 
(days)" 
7,2 ± 0,8 100 ± 13 ( 2-183) 
3,7 ± 0,7** (0-5,5) 47 10++(3-85) 
Eicosapentaenoic acid 1% 
(20,5 n-3) (n=8) 3,3 ± 0,5***(2-5,5) 4,3 ± 0,8* (1,5-7) 60 ± 11++(22-118) 
Dihomo-y-linolenic acid 1% 
(20'3 n-6) (n=8) 
y-linolenic acid 1% 
(18'3 n-6) (n=8) 
Arachidonic acid 1% 
(20,4 n-6) (n=8) 
AUC: area under the curve 
: mean ± SEM (range) 
3,9 ± 0,5** (2-5,5) 
4,6 ± 0,5* (2,5-6) 
5,3 ± 1,0 (2-9,5) 
4,9 ± 0,9 (1,5-9) 70 ± 15+ (18-152) 
4,8 0,6** (2-7) 71 ± 12++(24-100) 
6,4 ± 1,0 (0-8) 97 ± 21 ( 16-201) 
Significance of difference vs controls for duration of corneal opacity and vessel growth was 
calculated with the Mann-Whitney U test. 
P < 0,05; ** P < 0,01; *** F < 0,002 
Mean pachymetry values of controls and treated animals at various points during the inflam-
mation were tested for sig~ificance with Wilcoxon's signed rank test 
+ p < 0,05; p < 0,01 
( 22:4 n=6) was decreased in the same ratio as in 
the controls to 2,5% and 1,9% respectively. The 
oleic acid (18:1) level decreased and the palmitic 
acid (16:0} level increased in the corneal phos-
pholipids of EPA and columbinic acid treated ani-
mals. 
The total amount of the free fatty acids was 4% 
of the ampunt of phospholipid bound fatty acids. 
Columbinic acid and EPA occurred in the free fatty 
acid fraction, however the level of these fatty 
acids was low compared to the phospholipid bound 
fraction. 
DISCUSSION 
Treatment with the fatty acids columbinic acid, 
EPA and y-linolenic acid was effective in the 
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inhibition of leukocyte infiltration, neovascu-
larization and corneal edema formation. Regarding 
neovascularization and corneal edema, columbinic 
acid showed the most effective inhibition. EPA was 
the most effective inhibitor of leukocyte infil-
tration. DHGL showed a significant inhibition of 
leukocyte infiltration and edema formation but not 
of neovascularization. Arachidonic acid treatment 
had neither an inhibitory nor a stimulating effect 
o~ the parameters of the immune-complex keratitis. 
Because we counted the number of days corneal 
opacification was visible and not the number of 
leukocytes involved, we could have underestimated 
the effect of the fatty acids used in this model 
of corneal disease. In our impression the number 
of days on which corneal opacification occurred 
were directly correlated with the area of corneal 
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TABLE II 
THE EFFECT OF TOPICAL ADMINISTRATION OF COLUMBINIC ACID (18'3 5,9,12) OR EICOSAPEN-
TAENOIC ACID (20'5 n-3) ON THE COMPOSITION OF RABBIT CORNAL TISSUE PHOSPHOLIPID 
BOUND AND FREE FATTY ACIDS. 
Fatty acid Fatty acid composition (weight %) 
Numerical 
symbol 
Trivial name of 
of fatty acid 
Controls Columbinic acid Eicosapentaenoic acid 
PL FFA PL FFA PL FFA 
16' 0 palmitic 10.9 0.7 13.8 0.4 15.8 0.7 
18,0 stearic 8. 9 1.4 10.6 0. 9 9.0 1.1 
18,1 n-9 oleic 42.5 0.8 37.1 1.4 35.7 1.1 
18,2 n-6 linoleic 0.9 0.0 0.7 0.1 0.5 0.0 
18d n-6 (trans) colurnbinic 0.0 0.0 5.6 0. 4 0.0 0.0 
20 '4 n-6 arachidonic 7.5 0.0 5. 9 0. 2 4.9 0. 0 
20,5 n-3 eicosapentaenoic 0.0 0.0 0.0 0.0 1.8 0.1 
22,4 n-6 3.0 0.0 2.5 0.1 1.9 0.0 
22,5 n-3 0. 7 0.0 0.5 o.o 2.5 0.1 
22,6 n-3 docosahexanoic 0.3 0.0 0.0 0.0 0.3 0.0 
The numerical symbol designates the chain length and the number of double bounds of 
fatty acid, n designates the place of the first double bound. 
Values are the mean of two pooled corneal tissue preparations obtained from four 
different animals, extracted and analyzed as described in the Methods section. 
(PL =phospholipid bound fatty acids, FFA =free fatty acids). 
opacification. The same was observed for corneal 
neovascularization. 
All animals, treated with vehicle only, respon-
ded with corneal opacification, neovascularization 
and edema. The appearance of opaque rings and 
neovascularization in the cornea is in accordance 
with previous observations using this model of 
corneal anaphylaxis (16-18). 
Histology has shown that the opaque ring con-
sisted mainly of a polymorphonuclear leukocyte 
infiltrate (24). Chemotactic factors produced at 
the site of the antigen-antibody precipitate may 
attract leukocytes. The invaded leukocytes will 
produce prostaglandins and chemotactic leuko-
trienes {5,6). Prostaglandins, especially PGE1 and 
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PGE2 , have been determined as the most important 
stimuli for neovascularization {19}. The leukocyte 
products will result in even more leukocyte in-
filtrate, neovascularization and edema. Agents 
that can prevent the formation of prostaglandins 
and chemotactic leukotrienes in the cornea will 
eventually lead to a decrease of the inflammatory 
symptoms of immune complex keratitis {18). 
In vitro cyclooxygenase inhibition can be 
achieved in different ways; by enzyme inhibition 
with non-steroidal anti-inflammatory drugs {19} or 
by competition with structurally related fatty 
acids of arachidonic acid {20). Many different 
fatty acids can interact with the active'site of 
cyclooxygenase, but the number and position of the 
double bonds determine how well inhibitors can 
prevent synthesis of prostaglandin (20). Inhibi-
tion of lipoxygenase is possible by some experi-
mental compounds (21-23). Little is known about 
the competitive inhibitory effects-of fatty acids 
on the activity of lipoxygenase. 
Figure 2 shows a classification of the fatty 
acids we used in our experiments. We selected 
these fatty acids because of their different pos-
sible inhibitory effects on the formation of pros-
taglandins and leukotrienes from arachidonic acid. 
The y-linolenic acid and DHGL can be converted by 
desaturase enzymes to arachidonic acid (24). DHGL 
can also be converted directly to prostaglandins 
of the 1-series for example PGE 1 , by cyclooxyge-
nase and to 15 hydroxyeicosatetraenoic acid by 
lipoxygenase (25,26). EPA, a fatty acid found in 
fish oil prepared from various kinds of marine 
fishes, can be metabolized to prostaglandins of 
the 3-series and leukotrienes of the 5-series (27-
30). Columbinic acid is a newly discovered type of 
"..lnsaturated fatty acid of botanical origin (31) 
. 3.nd differs in its structure from y-linolenic acid 
by cis-trans isomerie at one of the double bonds. 
Formation of the arachidonic acid by desaturation 
can not take place from this fatty acid (31,32). 
DHGL and arachidonic acid possess the same sub-
strate specificity for the production of prosta-
glandins by cyclooxygenase (33), but biological 
activity of PGE1 (DHGL-derived) is less compared 
to PGE2 (arachidonic acid-derived) (33). Substrate 
specificity of EPA for cyclooxygenase is much less 
in comparison with arachidonic acid and DHGL (33). 
EPA-derived PGE 3 -formation hardly takes place in 
vivo in the rabbit eye ( 34). 
We determined the incorporation of the two most 
efficient inhibitors of immunogenic keratitis, EPA 
and columbinic acid in the cornea after four days 
of topical application. Both EPA and columbinic 
acid showed an efficient incorporation into the 
phospholipids of the cornea, with concomittant 
lower levels of arachidonic acid, free fatty acid 
level was low. Phospholipase A
2
-activation by an 
inflammatory stimulus therefore may lead to a 
release of these poly-unsaturated fatty acids 
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besides lower levels of the naturally occurring 
ararchidonic adcid from the cell membranes of 
corneal tissue. 
In conclusion local application of unsaturated 
fatty acids opens new perspectives in the treat-
ment of corneal inflammatory diseases through 
modulation of the inflammatory response resulting 
in less leukocyte infiltration, neovascularization 
and corneal edema formation. 
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Ginkgo/ides - Chemistry, Biology, Pharmacology 
and Clinical Perspectives. P. Braquet (Ed.) 
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INTERFERENCE OF A GINKGOLIDE 
WITH MODELS OF CORNEAL 
DISEASES 
Nicolas L.J. Verbeij and Nicolas J. van Haeringen 
The Netherlands Ophthalmic Research Institute, Amsterdam, The 
Netherlands 
INTRODUCTION 
Platelet-activating factor (1-0-alkyl-2-acetyl-glycero-3-phosphocholine, 
P AF-acether) is one of the most potent inducers of platelet aggregation and 
has a wide spectrum of biological activities as a very potent mediator of 
inflammation, increasing vascular permeability. 
A specific P AF-acether antagonist BN 52021, a ginkgolide isolated from 
Ginkgo biloba extract which interferes with receptors for P AF-acether (3), 
is now available. 
Various cell types are potential sources for the formation of P AF-acether 
in pathophysiological conditions; P AF-acether is released during chemical 
or immune stimulation of neutrophils, vascular endothelium, thrombocytes 
and macrophages (2, 12). 
In the eye, P AF-acether decrease the biwave response of the rat elec-
troretinogram in vitro (6), and when systemically administered P AF-acether 
gives rise to edema of the rabbit retina in vivo (4). Treatment with the 
Ginkgo biloba extract resulted in protection of the retinal tissue against 
argon laser damage (5). 
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In the cornea, implantation of polymere pellets impregnated with P AF-
acether causes formation of newly formed vessels in this normally non-
vascular tissue (9). 
Immune keratitis can be used as a model to evaluate the effect of drugs 
on leukocyte infiltration, neovascularization and edema in corneal tissue. 
The participation of mediators in this pathology is beginning to be 
demonstrated but the results obtained on animal models with specific in-
hibitors of cyclooxygenase are contradictory. Corticosteroids prevent the 
occurrence of keratitis completely and nonsteroid antiinflammatory drugs 
such as indomethacin demonstrated inhibition of leukocyte infiltration at 
high concentrations (1). However, at lower concentrations an increase of 
leukocyte inflltration was observed (11), indicating that inhibition of the 
formation of prostaglandins in the cyclooxygenase pathway may facilitate 
the generation of leukotrienes in the lipoxygenase pathway and that at high 
concentrations inhibition of both pathways takes place. 
In order to clarify the possible role for P AF-acether in the model of cor-
neal inflammation and in corneal wound healing we investigated the effect 
of topical application with the PAF-acether receptor antagonist BN 52021. 
MATERIALS AND METHODS 
Animals 
Male pigmented Chinchilla rabbits (2-2.5 kg) were sedated with Hypnorm 
(fluanison 10 mg/ml and phentanyl citrate 0.2 mg/ml) 0.75 ml/kg body 
weight and oxybuprocain (novesin) was applied on the cornea for topical 
anesthesia. 
Corneal Denudation 
The entire corneal epithelium was removed from both eyes by scraping with 
a perpendicular blade from limbus to limbus. The removal of the corneal 
epithelium was performed carefully in order to preserve as far as possible 
the integrity of the basement membrane (Fig. 1). 
Immune Keratitis 
Immunization was performed by injection of 20 p.l of pyrogen-free human 
serum albumin (200Jo solution) using a 27 gauge needle in the corneal stroma 
of both eyes according to Morawiecki (8) (Fig. 2). 
Wound Healing 
Wounds after corneal scraping were stained with fluorescein (0.25% solu-
tion of fluorescein sodium), the eye W<!S washed with NaCl 0.90Jo in order 
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CORNEAL ABRASION 
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Figure 1 Schematic representation of corneal denudation. 
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Figure 2 Schematic representation of the model of immunogenic keratitis. 
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to remove excess fluorescein and photographed at regular time intervals 
until healed. Photographs were projected and wounded areas were deter-
mined by planimetry. Results were calculated in percent re-epithealization 
of the cornea. 
Corneal Thickness 
Corneal thickness was measured With a Haag-Streit slit lamp and 
pachometer, fitted with central fixation lights according to Mishima and 
Hedbys (7). The use of the fixation lights is essential in order to obtain 
consistent measurements of central corneal thickness. From each eye the 
mean of three measurements was taken. The difference between the cor-
neal thickness after and before abrasion or immunization is presented as 
corneal thickness. 
In the immune keratitis experiment for each animal the values of both 
eyes were averaged. 
The observations were organized in a masked fashion, where the observer 
was not aware of the schedule of drug treatment. 
Corneal Aspect 
The number of days was recorded during which a white ring or a diffuse, 
completely opaque cornea was present and during which neovasculariza-
tion was visible. 
Drug Treatment 
BN 52021 was freshly prepared every day as a 1 OJo suspension in viscous 
ophthalmic solvent containing 0.5% hydroxypropylmethylcellulose and 
0.9% NaCl without addition of preservatives. 
In the corneal abrasion experiment in eight rabbits at random one eye 
was treated with 30 pl of a 1% suspension of BN 52021 and the other eye 
with the vehicle, three times daily by instillation into the conjunctival sac. 
Treatment started one day before abrasion and continued for the duration 
of the experiment. 
In the immune keratitis experiment in eight rabbits both eyes were treated 
with 30 p.l of BN 52021 and in eight rabbits both eyes received the vehicle 
three times daily by instillation into the conjunctival sac. Treatment started 
eight days after immunization and continued for the duration of the 
experiments. 
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RESULTS 
Imm.une Keratitis 
Seven to ten days after intracorneal injection of HSA the appearance of 
keratitis in the eyes of the v·~hicle-treated rabbits started with clouding of 
the cornea at the limbus and between day 14 and 17 an opaque ring was 
formed, known as Wessely's ring (13), remaining for one to eight days. 
Sometimes the whole cornea became completely opaque in this period. Two 
to four days after the appearance of the white ring vascularization of the 
cornea started from the limbus and progressed until about day 24 and then 
regressed quickly, resulting in all cases in a clear cornea 30 days after im-
munization. Swelling of the cornea as recorded by pachometry started at 
about eight days after immunization and lasted until about day 30. 
All animals injected with HSA responded with white ring formation and 
neovascularization. Control rabbits with normal cornea treated with BN 
52021 showed no changes in the aspect of the cornea. 
In rabbits treated with BN 52021 the period of corneal opacification was 
significantly shorter but not the period of neovascularization, as compared 
to that in non-treated animals (Table 1). The extent of swelling, determin-
ed as mean area under the curve (Fig. 3), was significantly different from 
that in untreated controls. 
Table 1 Immunogenic keratitis in rabbits treated with topical BN 52021 
Controls (n = 8) 
BN 52021 10Jo (n=8) 
AUC: area under the curve. 
All values are mean + SEM. 
Period of corneal 
opacity 
(days) 
5.5+0.7 
2S+1.6 
Period of corneal 
neovascularizatio-
n 
(days) 
6.8+ 1.6 
7.0+ 1.6 
•Mann-Whitney U test (P<0.05 for BN 52021 vs. control). 
*Wilcoxon's signed rank test (P<O.Ol for BN 52021 vs. control). 
Corneal Abrasion 
Pachometry 
AUC 
(OJo of control) 
100+23 
59*+21 
In the vehicle-treated eyes complete restoration of the corneal surface was 
observed by 168 hours after scraping of the epithelium. 
In all animals improvement was observed in the treated eye at 6 hours 
with complete restoration at 96 hours (Fig. 4). 
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Figure 3 Effect of treatment with eye drops containing I OJo BN 52021 ( •) on corneal thickness as com-
pared to vehicle-treated controls (0) in rabbit~ during inunune keratitis provoked by injection with human 
serum albumin (HSA). 
100 
ro 
QJ 80 c 
0 
t) 
1l 
.!::! 60 ~ e--e BN 52021 
Qi o-o controls 
~ 
=§. 
QJ 
I 40 
~ 
?!!-
20 
0 
0 6 24 48 72 96 168 
hours 
Figure 4 Effect of treatment with eye drops containing I% BN 52021 ( •) on corneal re-epithelialization 
as compared to vehicle-treated controls (0) in rabbits after corneal denudation. 
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Corneal swelling in vehicle-treated eyes was observed until168 hours after 
scraping of the epithelium. In the eyes treated with BN 52021, after 6 hours 
less swelling was recorded as compared to the vehicle-treated contralateral 
eye. This difference in swelling persisted until at 168 hours after scraping 
the corneal swelling in the treated eyes had disappeared and the corneal 
thickness was the same as before the experiment (Fig. 5). 
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a; 
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<Jl 
'" 
Ql 
c: 
C; 0.10 <) 
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0.00 
0 6 24 48 72 96 120 168 
hours 
Figure 5 Effect of treatment with eye drops containing I "lo BN 52021 (e) on corneal swelling as com-
pared to vehicle-treated controls (0) in rabbits after corneal denudation. 
DISCUSSION 
From a therapeutic point of view topical treatment of affections of the eye 
has the advantage of a direct accessibility to the surface of the eye with 
medications and the possibility of rapid resorption through the cornea into 
the inner eye. In our experiments a viscous solvent was used, giving a longer 
cornea-contact time, in order to promote local drug resorption into the 
cornea. 
In preliminary experiments with the model of immune keratitis we tried 
to ameliorate drug resorption in the cornea by removal of the corneal 
epithelium, which might be a barrier against drug penetration. There was 
no difference in the observed effect of BN 52021 on immune keratitis; 
however, it was striking that the epithelial defect healed earlier in the eye 
treated with BN 52021 as compared to the vehicle-treated contralateral eye. 
This prompted us to investigate in a separate experiment the effect of BN 
52021 after corneal denudation in a normal eye. 
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The effect of the specific P AF -acether antagonist BN 52021 on leukocyte 
infiltration and corneal swelling in immune keratitis and on wound healing 
and corneal swelling after corneal denudation reveal a role for P AF-acether 
in these signs of ocular inflammation. Rochels (9) proved that P AF-acether, 
implanted in polymere pellets in the rabbit cornea, gives rise to 
neovascularization. This process of PAF-acether-induced corneal 
neovascularization can be fully inhibited by topical treatment with in-
domethacin, suggesting the formation of prostaglandins as a necessary step 
in the growth of new vessels. If there exists a positive feedback system be-
tween P AF and prostaglandins in the inflamed cornea this system is not 
inhibited efficiently enough by BN 52021 to prevent to some extent 
neovascularization. 
In both models BN 52021 was given prophylactically before signs of in-
flammation started to occur. Corneal thickness in immune keratitis was 
only influenced before and after maximal swelling in contrast to the swell-
ing after denudation, which was directly less intensive from the beginning 
and throughout the experiment. 
From studies with nonsteroidal antiinflammatory compounds such as in-
domethacin and flurbiprofen it is known that prostaglandins probably do 
not play a role in conjunctival epithelial cell migration after corneal denuda-
tion (10). The time-related effect of BN 52021 on corneal swelling andre-
epithelialization already within six hours after corneal denudation and the 
parallel in the course of these parameters until complete healing of the cor-
nea suggest a common cause mediated by PAF-acether. From the ex-
periments it cannot be determined if improved healing of corneal wounds 
is the cause or the effect of decreased corneal swelling. 
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The Influence of a Fish Oil Dietary Supplement 
on Immunogenic Keratitis 
Nicolas L. J. Verbey• and Nicolas J. van Haeringent 
Fish lipids contain large amounts of eicosapentaenoic acid (EPA) and docosahexaenoic acid. These 
fatty acids are known to have an influence on prostaglandin (PG) and leukotriene (LT) synthesis. We 
studied the effect of a fish oil dietary supplement on an immune-complex-induced keratitis of the 
rabbit eye and compared it with the effect of a sunflower seed oil dietary supplement, rich in linoleic 
acid. Immune complex keratitis induced by intrastromal injection of human serum albumin (HSA) was 
characterized by leukocyte infiltrate, neovascularization, and corneal edema. Animals given a fish oil 
diet showed significantly less leukocyte infiltrate, neovascularization, and corneal edema, compared to 
those given a sunflower seed oil diet. Invest Ophthalmol Vis Sci 31:000-000, 1990 
Prostaglandins (PGs) and leukouienes (L Ts) play 
an important role in ocular intlammation. 1-• PGs 
contribute to the formation of edema and ery-
thema.9·10 L TB4 is a potent chemotactic agent that 
plays a role in the migration ofleukocytes into sites of 
intlammation. 11- 13 These intlammatory mediators 
are derived from the fatty acid arachidonic acid (AA) 
by metabolic conversion catalyzed by the enzymes 
cyclooxygenase and lipoxygenase (Fig. I). AA is re-
leased from the phospholipids of the. cell membrane 
in response to injury or intlammation by phospholi-
pase A2• 14 In addition to AA, some other fatty acids, 
such as eicosapentaenoic acid (EPA) and dihomo-)'-
linolenic acid (DHGL), may also give rise to PG and 
LT formation. IfPGs and LTs are synthesized from a 
fatty acid, each fatty acid has its own PG and L T 
counterparts with different chemical structures and 
biologic behaviorsY 
The fatty acid composition of the diet determines 
the ratio in which fatty acids are incorporated into the 
phospholipids of the cell membrane." There is con-
siderable evidence that human populations whose di-
etary protein is mainly derived from fish are at low 
risk for cardiovascular disease. 17-11 A starch- and ca-
sein-derived diet containing 6.7% fish oil has shown a 
beneficial mfluence on edema formation. systemic 
lupus erythematosus, immunologically induced ar-
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thritis. and glomerulonephritis in experimental ani-
malsY-16 Fish lipid contains large amounts of EPA 
and docosahexaenoic acid (DCHA), which are only 
very minor components of food derived from terres-
trial plants and animals. EPA and DCHA as dietary 
supplements lead to diminished synthesis of PGE1 
and L TB41"·17-30 as a result of competitive inhibition 
of metabolism of AA in the cyclooxygenase and li-
poxygenase pathways by EPA and the formation of 
PGE3 and LTB5 from EPA (Fig. 1). 15•1"-33 Rabbit. 
monkey, and human uvea and conjunctiva are able 
to metabolize EPA to PGE3 and L TB, in vitro.3"·3' 
A type III immune complex reaction of the rabbit 
cornea can be used as a model for testing anti-intlam-
matory properties of drugs. In this animal model. 
after intrastromal injection of antigen. the eye first 
remains quiet for 10-14 days. During this time. spe-
cific antibody production is generated in the local 
draining lymph nodes and spleen. An abrupt onset of 
intlammation occurs when sufficient specific anti-
body complexes with local antigen. These antibody-
antigen complexes activate the complement cascade 
with the production of chemotactic factors that are 
responsible for polymorphonuclear cell infiltration.3" 
These polymorphonuclear leukocytes (PMLs) pro-
duce, among others, AA products. PGs and L Ts are 
major !actors in neovascularization and edema for-
mation of the cornea as well as in the positive feed-
back mechanism of PML infiltrate formation. 37 
We compared the intluence of a diet containing 
6.7% fish oil and 2.7% sunflower seed oil with a diet 
containing 9.4% suntlower seed oil. rich in linoleic 
acid (LA), on the clinical appearance of human 
serum albumin (HSA)-induccd immunogenic kera-
titis in rahbits. 
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5 - lipoxygenase 
Fig. I. PGE and L TB formation from their precursor limy acids. 
OCHA. docosahexaenoic acid: EPA. t:icosa~ntat:noic acid: LA. 
linoleic acid; DHGL. dihomo-...,.·linolenic acid. •. Competitive in-
hibition. 
Materials and Methods 
Animals 
The experiments were performed in male pig-
mented chinchilla rabbits weighing at least 2.0 kg. All 
eyes were initially examined with a slit lamp. Only 
animals without any sign of ocular intlammation 
were included in the study. All procedures in this 
study adhered to the ARYO Resolution of the Usc of 
Animals in Research. 
75 
Diet and Feeding Procedures 
The rabbits were maintained on standard rabbit 
diet (Hope Farms, Woerden, The Netherlands) prior 
to commencing the experimental diet. Because suffi-
cient control of the exact fatty acid composition of a 
commercial rabbit diet is not possible. we chose a 
semi-synthetic experimental diet in which the com-
position of nutrients can be controlled exactly. Both 
diets contained 2. 7% sunflower seed oil, and the total 
fat was increased to 9.4% by adding either 6.7% more 
sunflower seed oil or 6.7% fish oil. These two diets 
will be referred to as "the sunflower seed oil diet" and 
"the fish oil diet". The composition of the experi-
mental diets is given in Tables I and 2. 
Diet and water were given ad libitum to both 
groups. Body weight was measured twice a week. 
The diet for the two groups of rabbits contained 
30.1 g fat per 1.000 kcal (energy = 28%. weight 
= 9.4%). The fish oil was extracted from mackerel 
and contained 13.3% EPA (20:5) and 7.1% 
DCHA (22:6). 
The animals were gradually acclimated to their ex-
perimental dietary supplements in live steps of 2 
weeks each. At each step a higher percentage of the 
standard diet was replaced by the experimental diets. 
The animals were kept for at least 6 months •Jn a 
100% semi-synthetic diet prior to the experiments. 
(Materials for the diets were provided by Unilever. 
Ylaardingen, The Netherlands.) Weights were similar 
in rabbits fed with fish-oil-enriched or sunflower seed 
oil enriched food at the completion of this feeding 
period. Before the start of adjusting the animals to the 
experimental diets, weights were 1450 ± 36 g and 
1514 ± 44 g, and at the time of the keratitis t!Xpt!ri-
ments were 2751 ± 101 g and 2625 ± 115 g (mt!an 
± SEM), respectively, for the animals that receivt!d 
the sunflower seed oil diet or fish oil diet. 
Immunization 
Immunization of the pigmented rabbits was per-
formed by injection of20 1'1 pyrogen-free HSA (20% 
solution; CLB. Amsterdam, The Netherlands) into 
the cornea of both eyes according to Morawiecki. 3" 
after corneal anesthesia with 0.4% Oxybuprocainc 
and sedation by Hypnorm'" (tluanison 10 mg/ml and. 
phentanyl citrate 0.2 mg/ml). 0. 75 ml/kg body 
weight. 
Parameters of Ocular Inflammation 
The effect of the dit!t on the clinical appearance of 
this HSA-induced immunogenic keratitis of the rab-
bit eye was evaluated hy measuring corneal edema 
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE / Augusr 1 990 Vol. J1 
Table L Composition of semi-synthetic rabbit diets 
Diet 
Fishuil 
(g/1000 
lngrediem k,·a!) 
Com starch• 140 
Cascint 62 
Crude fiber:j: 60 
Salts mixture§ 25 
Vitamin mixtureU 
Gr:>ss mealf 1.5 
Sulfaquinoxaline 0.04 
Fish oil 21.5 
Sunflower seed oil 8.6 
320.6 
• 4.1 kcal/g {N.Y. Honig's Artikelen. Koog a/d Qan. The Netherlands). 
t 4.1 kcal/g (D.M.V .• Veghel. The Netherlands). 
:; Sawdust (sterilized) (Broekman lnstituut. Someren. The Netherlands). 
§Composition in milligrams: CaC03 7250: CoSO, 0.3: Cu citr.lte I:!: 
F~III) citrate 290: KCI 5970: KH2 PO, 1930: KIO, 0.3: MgHP(),. 3H20 
6320: MnS0.·4H20 72: Na acetate 3100: Zn Citrate 35. 
formation. neovascularization. and the occurrence of 
an annular leukocyte infiltrate in the cornea (Wes-
sely's ring). 39 These three parameters of corneal in-
Table 2. The fatty acid composition of suntlower 
seed oil and fish oil used in the experimental diets 
Numerical 
symbol 
14:0 
15:0 
16:0 
16:1 (n = 7) 
17:0 
18:0 
18:1 (n = 9) 
18:2 (n = 6) 
I8:4(n = 3) 
20:0 
20:1 (n = 6) 
20:4 (n = 6) 
20:5 (n = 3) 
22:0 
22:1 (n = 3) 
22:5 (n = 3) 
22:6(n = 3) 
Total 
Fauyacid 
Fuuyadd 
compo.\'itwn 
(Wt/Wt%) 
Sunflower 
Trivlal name w.!ed mt• 
myristic 0.1 
pentedecanoic 0.1 
palmitic 7.1 
hexadecanoic 0.1 
heptadetanoic 0.1 
stearic 4.3 
oleic I X.X 
linoleic (LA) 6X.J 
octadecatetranoic 
arachidic 0.3 
eicosenoic 0.2 
arachidonic (AA) 
eicosapentaenoic {EPA) 
behenic 0.6 
erucic 
docosapentaenoic 
docosahexaenoic (DCHA) 
100.0 
Fish 
f1llt 
11.5 
24.1 
12.4 
3.7 
14.9 
1.4 
4.0 
1.5 
0.7 
12.3 
1.0 
2.1 
9.0 
100,0 
The numbers are the percentages or total tatty ac1ds. The numencal ~ym­
hol designates the chain length and the numher nt' Juuhh: hnnds 10 the IUuy 
acid. and n dcsignatt."S the place of the lir:o;t douhlc honU. ~ounun~ frum the 
methyl end. 
• Union N.Y .. Antwerp. Belgium. 
t Unimalls R.V .• ZwijnUrecht. The NctherlanU~. 
Sunj/ower 
seed oil Energy 
(%) 1.~1 /000 kca/) ~VeixJu (%) 
140 43.7 49 
23 62 19.3 
60 18.7 
25 7.8 
0.6 
1.5 0.5 
0.04 0.0 
6.7 20 
30.1 2.7 9.4 8 28 
320.6 100 100 100 100 
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11 Composition in milligrams: vitamin A acetate 12: p-ammo-benzoic actd 
147: biotin 0.5: cholecalciferol 5: choline 587: all-r:ac-a-tocopherol-acetate 
60: folic acid 3: m.vr~inositol 294: vitamin K 5: nicotinamide ~5: panto-
thenic acid (Ca salt) 17, pyridoxine 7: riboflaVin 7: thiamm ( monocitratel lit 
' COOperative Landbouwveremgjng .. De Samenwerking ... Maasland. The 
Netherlands. 
flammation can be well obsLrved in vivo. The clinical 
observation was organized in a masked fashion. 
Corneal aspect: The number of days during which 
opaque rings or a diffuse completely opaque cornea 
were visible were recorded from color slides taken 
daily (tlash intensity 50 mW. distance 5 em). For each 
aniinal the values of both eyes were averaged. 
Neovasczdari=ation: The extent of vessel growth 
into the cornea was determined every other day from 
the color slides. Diapositives were projected and en-
larged 12 times. By planimetry the area with new 
vessels was determined as a percentage of the total 
corneal surface. The percentage of vessel growth was 
plotted against time in days, and from these graphs 
the area under the curve was measured by planime-
try. For each animal the values of both eyes were 
averaged. 
Pachymetry: A Haag-Streit slit lamp with a pachy-
meter fitted with central fixation lights according to 
Mishima and Hedbys"" was used for these measure-
ments. The use of the fixation lights is essential in 
order to obtain consistent measurements of central 
thickness. In inflamed edematous corneas. pachy-
metry measurements were subject to greater inaccu-
racy. which. however, did not exceed a relative mea-
surement error of 5%. From each eye the mean of 
three measurements was taken. For each animal the 
values of both eyes were averaged. 
Centml corneal thickness was measured before in-
tracorneal injection with HSA and every other day 
from day 7 until day 29. For each animal the differ-
ence between pachymetry measurement bt:!orc intra-
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ocular injection with HSA and the measurement at 
any time thereafter was recorded as the change in 
corneal thickness. For each animal the corneal thick-
ness was plotted in time, and from this graph the area 
under the curve was measured. 
Determination of Anti-HSA Immunoglobulins by 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Serum was obtained from the rabbits of the two 
dietary regimens on day 29 after the first intracorneal 
injection with HSA. Microcuvettes (Gilford, Cleve-
land, OH) were coated with coating buffer containing 
10 JLg/ml of the HSA, used as antigen for the intra-
corneal injections on day 0. After a coating period of 
I hr at room temperature the cuvettes were washed 
three times with phosphate-buffered saline (PBS) 
containing 0.1% Tween 80. Subsequently 250-JLI 
serum samples, diluted 1/10.000 in 0.1% Tween in 
PBS were added to the cuvettes. After an incubation 
period of 1 hr at room temperature the cuvettes were 
washed three times with 0.1% Tween in PBS. Subse-
quently the cuvettes were incubated with a 1/500 di-
lution of peroxidase-conjugated goat anti-rabbit im-
munoglobulin for 1 hr at room temperature (Nordic, 
Tilburg, The Netherlands). After being washed three 
times with 0.1% Tween in PBS. bound perox-
idase-labeled antibody was developed at room 
temperature by adding 350 !Ll ABTS solution 
(0.16 mM 2,2-azino-di-3-ethyl-benzthiazoline-6-sul-
phonate [Boehringer, Mannheim, West Germany] + 
CU5% H20 2 in 0.05 M citric acid. pH 4.0). The green 
reaction product was measured after 20 min in a 
spectrophotometer (E!A; Gilford) at 405 mm. 
As a standard, a sample of purified rabbit anti-HSA 
immunoglobulin was used. This standard contained 
10.000 ELISA units per 0.37 !Lg rabbit anti-HSA im-
munoglobulin. 
Statistical Analysis 
Data were analyzed by nonparametric methods to 
avoid assumptions about the distribution of the vari-
ables involved. 
Wilcoxon's signed-rank test was applied for pachy-
metry data obtained in the treated and untreated 
groups during the period of inflammation. The 
Mann-Whitney U-test was applied for the difference 
in the area under the curve of neovascularization and 
for the difference in the duration of corneal opacifi-
cation between dietary groups. Significance of differ-
ence was obtained from a table for two-tailed obser-
vations, and P values < 0.05 were regarded as signifi-
cant. All values are given in mean± SEM. 
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Results 
Clinical Observations 
The appearance of keratitis in rabbits fed a sun-
flower seed oil diet was as follows. One week to 10 
days after intracomeal injection of HSA. clouding of 
the cornea sta.rted at the limbus, and on approxi-
mately days 14-17 a white ring of opacification, also 
called Wessely's ring, formed. 39 This ring was present 
for 1-8 days. Two to 4 days after Wessely's ring was 
first noted, neovascularization of the cornea staned 
from the limbus. The neovascularization progressed 
until approximately days 22-25 and then regressed 
quickly. In all cases we observed a dear cornea 30 
days after the injection of the HSA. 
All animals injected with HSA responded with 
white ring formation and neovascularization. Cor-
neal edema formation. recorded with pachymetry. 
staned around day 7 and lasted until day 30 (Fig. 2. 
Table 3). 
In the rabbits fed a fish oil diet. the period of cor-
neal opacification was significantly shoner compared 
to that of animals fed a sunflower seed oil diet (Fig. 3. 
Table 3). Moreover. the white ring frequently ap-
peared incomplete. and corneal opacification was less 
intense. Vessel growth measured as area under the 
~CORNEAL THICKNESS lmm) 
0.5 --.... sunflower oil diet 
o--o fish oil diet 
0.1. 
0.3 
-0.1 
o 7 g n o ~ n ~ ~ n ~ n ~ 
OAYS AFTER INTRACORNEAL INJECTION 
WITH HSA 
Fig. 2. Comparison of changes in mean corneal thicknL·ss dunng 
immunogenic kcrJ.titis tn:atcd with two diltl!rcnt dietary rcg1mens 
(fish oil diet. n .= X or sunllowcr seed oil Jict. n - 10). ~corneal 
thickness was calcul;.acd from the Uitli.:rcncc hc'tw~:cn the pachy~ 
mctry measurement hcf(.)n: intraocular injection with HSA amJ at 
any given time thereafter. 
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Table 3. Immunogenic keratitis in rabbits 
on a supplemented diet 
Diet 
Sunflower seed oil 
(n = 10) 
Fish oil (n = 8) · 
Duraiion of' 
corneal . 
opacit.,_,. 
(da_vs) 
4.8 ± 0.5 
2.6 ± 0.6; 
All values are mean ± SEM. 
Vessel 
growth 
AUC• 
(%) 
100 ± 1•5 
16 ± 8§ 
AUC. area under the curve (100% in sunflower seed oil diet). 
Corneal 
thickness 
.Wet 
.~ (%) 
100 ± 15 
27 :t 611 
• Significance of difference for duration of corneal opacity and vessel 
growth was calculated with the Mann-Whitney U-tesL 
t Mean comc:al thickness values of the animals on th~ two dietary regi-
mens at various time points during the inflammation were tested tOr signifi-
cance with Wilcoxon ·s signed r.mk test. 
; P< 0.01. 
§ p < 0.001. 
11 P< 0.005. 
curve was significantly diminished (Fig. 4. Table 3). A 
significant inhibition of corneal edema was noted in 
rabbits given a fish oil diet as compared to those given 
a sunflower seed oil diet (Fig. 2, Table 3). 
Systemic Antibody Response to 
Intracomeal Injected HSA 
There was no significant difference in systemic re-
sponse to HSA in the two different dietary regimens. 
Animals on a sunflower seed oil diet showed a serum 
level of 8.12 ± 2.17 1-'g/ml (mean ± SEM) of anti-
HSA lgG immunoglobulins, and those on a fish oil 
diet 8.38 ± 3.26 1-'g/ml serum (mean ± SEM). 
Discussion 
The three parameters of corneal inflammation we 
used, Wessely's ring, swelling, and neovasculariza-
tion, can be observed well in the model of immuno-
genic keratitis and are known to be at least partially 
OCCURENCE OF 
CORNEAL OPACITY 
"'· 100 
BO 
60 
LO 
20 
0 SUNFLOWER OIL 
IIlii FISH OIL 
22 
Fig. 3. Days on which opaque rings or a diliUsc t:omplctdy 
opaque cornea were visible during 1mmunoggnic kl!'ratius treated 
with two different dietary regimens (tish oil diet. n ~ X {)f sun !lower 
seed oil diet. n = 10). Corneal opacity was rcconJcd from color 
slides 1akcn daily. 
78 
~OVASCULARISATION 
% 
- SUNFLOWER OL 
30 
-FISH OIL 
20 
10 
15 19 21 23 25 27 29 
OAYS AFTER INTRA CORNEAL INJECTION WITH HSA 
Fig. 4. Comparison of changes in mean corneal neovasculariza-
tion during immunogenic keratitis treated with two ditferent di-
etary regimens (fish oil diet. n = 8 or sunflower seed oil diet. n 
= 10). Mean corneal neovascularization was calculated as percent-
age of total corneal surface by planimetry from color slides taken of 
the intlamed corneas. 
mediated by the formation of PGs and L Ts.41 ' 44 
Rabbits on a diet containing 9.4% sunflower seed oil 
were the controls in our study. For health reasons. in 
order to avoid deficiency of essential fatty acids the 
experimental group received 2.7% suntlower seed oil 
made up to 9.4% with fish oil. The values found for 
the parameters during immunogenic keratitis in the 
control group were not significantly different from 
those in rabbits maintained on standard rabbit diet. 37 
The suppressive effect of the fish oil dietary supple-
ment was significant on all three clinical parameters. 
Apart from a shorter period of infiltration with leu-
kocytes. the observed amelioration of the immuno-
genic keratitis by the diet may be due also to altered 
metabolic activity of the invaded leukocytes. Most 
authors consider the presence of PML in corneal in-
flammation responsible for the later development of 
neovascularization and the concomitant edema for-
mation_45 .... " Others believe that the corneal tissues. 
especially the epithelium, can produce chemotactic 
and neovasculogenic substances without the infiltra-
tion of the PML4'·50 In this case leukocytes are not a 
prerequisite ofneovascularization, but rather by their 
presence merely potentiate the neovascular response. 
Fish oil dietary supplementation may markedly 
alter the eicosanoid formation in endotoxin-induced 
anterior uveal inflammation; in contrast to our find-
ings in immunogenic keratitis. however, it has no 
effect on cellular infiltration. 51 This ditfercnct: in in-
flammatory response IS due possibly to ditferenccs in 
tissue synthesis ofL TB4 , a potent chemoattractant for 
leukocytes. The iris ciliary hody of the rahbit has low 
levels of lipoxygenase activity, unlike the cornea. in 
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which lipoxygenase activity is more prominent. 7 In 
our study the effect of fish oil supplement on corneal 
inflammation may be ascribed to a diminished syn-
thesis of PGs in the cornea by EPA- and DCHA-in-
duced inhibition of cyclooxygenase and to the for-
mation of the less active L TB5 and PGE3 from EPA (Fig. 1 ). 27-JJ 
In immunochemical keratitis the reaction in the 
cornea starts with the formation of antibody-antigen 
complexes.46 Although an effect of the EPA-enriched 
diet on antibody formation has been observed, 52 in 
our experiments a diet containing EPA compared to 
one containing LA does affect the systemic antibody 
response to HSA. 
Key words: fish oil, keratitis. eye. prostaglandin. leuko-
triene 
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10. Conclusions 
The steroid medrysone and IBMX are effective inhibitors of 
several inflammatory responses in the human serum albumin induced 
immune complex uveitis. Medrysone protects the eye against blood-
aqueous barrier disruption as well as against cellular infiltra-
tion in immunogenic uveitis. IBMX only protects the blood-aqueous 
barrier but has no significant effect on cellular infiltration. 
The mechanism of action of corticosteroids is explained by 
the induced synthesis of lipocortins - specific proteins, that 
are inhibitors of phospholipase A2 . The mechanism of phosphodi-
esterase inhibitors in inflammation is explained by the intra-
cellular elevation of cAMP, which reduces the production of 
prostaglandin E2 in an immediate hypersensitive reaction. It is 
conceivable that IBMX decreases the production of PGs in the 
infiltrated leukocytes and that by this way the blood-aqueous 
barrier is protected in our model. 
In HSA induced immunogenic keratitis the suppressive effect 
of a local corticosteroid used as a positive control confirms 
earlier observations using this model. The lipoxygenase 
inhibitors Bay 08276 and Rev 5901 were both effective in the 
inhibition of leukocyte infiltration, neovascularization and 
corneal edema. 
Efficacy of inhibition of leukotriene B4 by Bay 08276 and 
Rev 5901 appears to coincide with inhibition of corneal opacity 
and thus of leukocyte infiltration and neovascularization. Less 
· inhibition of edema by Rev 5901 as compared to Bay 08276 may be 
related to absence of any effect on PG formation, whereas Bay 
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08276 is less specific and may also inhibit PG formation. 
Suprofen as inhibitor of PG and not of LTB4 formation only 
effects edema formation efficiently and has little effect on 
neovascularization and no influence on corneal opacity. 
Our conclusion is that the lipoxygenase inhibitors used by 
us, have a strong inhibiting influence on symptoms of corneal 
inflammation. In view of the known undesirable side effects of 
steroids these drugs may be of interest as topical ophthalmic 
preparations. 
Treatment of immunogenic keratitis with the fatty acids 
columbinic acid, eicosapentaenoic acid and gamma-linolenic acid 
was effective in the inhibition of leukocyte infiltration, nee-
vascularization and corneal edema formation. Columbinic acid 
showed the most effective inhibition with regard to neovascu-
larization and corneal edema. Eicosapentaenoic was the most 
effective inhibitor of leukocyte infiltration. Dihomo-gamma-
linolenic acid showed a significant inhibition of leukocyte 
infiltration and edema formation but not of neovascularization. 
Arachidonic acid treatment had neither an inhibitory nor a 
stimulating effect on the parameters of the immune-complex 
keratitis. 
We determined the incorporation of the two most efficient 
inhibitors of immunogenic keratitis, EPA and columbinic acid, in 
the cornea after four days of topical application. Both EPA and 
columbinic acid showed an efficient incorporation into the 
phospholipids of the cornea, with concomitant lower levels of 
intracorneal arachidonic acid; free fatty acid was low. Phospho-
lipase A2-activation by an inflammatory stimulus therefore may 
lead to a release of these poly-unsaturated fatty acids besides 
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lower levels of the naturally occurring arachidonic acid from the 
cell membranes of corneal tissue. 
In conclusion local application of unsaturated fatty acids 
opens new perspectives in the treatment of corneal inflammatory 
diseases through modulation of the inflammatory response 
resulting in less leukocyte infiltration, neovascularization and 
corneal edema formation. 
The effect of the specific PAF-acether antagonist BN 52021 
on leukocyte infiltration and corneal swelling in immune kerati-
tis revealed a role for PAF-acether in these signs of ocular 
inflammation. The effect of BN 52021 after corneal denudation in 
a normal eye showed a significant therapeutic effect on wound 
healing and corneal swelling after corneal denudation. 
A common cause mediated by PAF-acether was suggested by the 
time-related effect of BN 52021 on corneal swelling and re-epi-
thelialization within six hours after corneal denudation as well 
as by the parallel course of these parameters until complete 
corneal healing. From the experiments it cannot be determined if 
improved healing of corneal wounds is the cause or the effect of 
decreased corneal swelling. 
For the study on the influence of a fish oil diet on ocular 
inflammation, we used the model of immunogenic keratitis. The 
immunogenic keratitis could be significantly suppressed by an 
eicosapentaenoic acid containing fish oil diet. Significance was 
obtained on all three clinical parameters and was an indication 
for altered formation of PGs and LTs. Rabbits on linoleic acid 
enriched diet were the controls in our study. The values found 
for the parameters during immunogenic keratitis were not 
significantly different from those in rabbits maintained on 
83 
standard diet. 
In immunochemic keratitis the reaction in the cornea started 
with the formation of antibody antigen complexes. Although an 
effect of the EPA enriched diet ·on antibody formation had been 
observed, in our experiments feeding of EPA did not have an 
effect on the systemic antibody response to HSA. 
In conclusion EPA feeding had a significant inhibitive 
effect on immune complex inflammation of the rabbit cornea. 
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11. summary 
The effect of topical administration of 3-isobutyl-methyl-
xanthine (IBMX), a potent phosphodiesterase inhibitor, was 
studied on an experimentally provoked uveitis in rabbits. After 
presensitization with an intravitreal injection of human serum 
albumin (HSA) intravenous antigenic challenge induced blood-
aqueous barrier breakdown and leukocyte infiltration. Treatment 
with IBMX 1% two times daily, significantly inhibited the break-
down of the blood-aqueous barrier and the increase in PGE2 level 
of the aqueous humor. There was no effect on leukocyte infiltra-
tion. The therapeutic effect of IBMX in blood-aqueous barrier 
protection was comparable with the effect of topical treatment 
with the corticosteroid medrysone. 
Intrastromal injection with HSA in the rabbit cornea induced 
edema and a ring-shaped leukocyte infiltrate followed by neovas-
cularization. 
The effect of topically administered lipoxygenase and cyclo-
oxygenase inhibitors and a PAF-acether antagonist on this inflam-
matory keratitis was studied. Also the topical and systemic 
application of several unsaturated fatty acids were evaluated. 
The lipoxygenase inhibitors Bay 08276 and Rev 5901 and the 
cyclooxygenase inhibitor suprofen were given as 1% eye drops 
three times daily during the experiment. In eyes treated with 
lipoxygenase inhibitors leukocyte infiltration, neovasculariza-
tion and edema formation decreased. In eyes treated with a 
cyclooxygenase inhibitor the period of neovascularization was 
slightly shortened and corneal edema decreased. No influence on 
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leukocyte infiltration was seen. 
Several unsaturated fatty acids are precursors of prosta-
glandins and leukotrienes. Depending on their precursor, these 
prostaglandins and leukotrienes have different biological 
characteristics. Arachidonic, gamma-linolenic, dihomo-gamma-
linolenic (DHGL}, eicosapentaenoic (EPA} and columbinic acid were 
given as eye drops 0.5% three times daily during the experiment. 
Eicosapentaenoic acid, DHGL, columbinic, and gamma-linolenic, but 
not arachidonic acid, showed a significant inhibition of either 
leukocyte infiltration, edema or neovascularization. The 
inhibitory effects of these fatty acids may be caused by topical 
inhibition of the formation of prostaglandins and leukotrienes in 
the arachidonic acid cascade in the rabbit cornea. 
Platelet activating factor (1-0-alkyl-2-acetyl-glycero-3-
phosphocholine, PAF-acether) is one of the most potent inducers 
of platelet aggregation and has a wide spectrum of biological 
activities as a very potent mediator of inflammation, increasing 
vascular permeability. 
We tested the PAF-acether antagonist BN 52021 in the models 
of corneal abrasion and immunogenic keratitis. It was applied 
three times daily as a 1% suspension. After corneal abrasion, in 
the vehicle-treated eyes complete restoration of the corneal 
surface was observed by 168 hours after scraping of the 
epithelium. In the eyes treated with BN 52021, after 6 hours less 
swelling was recorded as compared to the vehicle-treated contra-
latera~ eye. This difference in swelling persisted until at 168 
hours after scraping the corneal swelling in the treated eyes 
had disappeared and the corneal thickness was the same as before 
the experiment. 
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During immunogenic keratitis rabbits treated with BN 52021 
showed a significantly shorter period of corneal opacification. 
The period of neovascularization was not different from that in 
non-treated animals. The extent of swelling, determined as mean 
area under the curve, was significantly different from that in 
untreated controls. 
Fish lipids contain large amounts of eicosapentaenoic acid 
and docosahexaenoic acid. These fatty acids are known to have an 
influence on prostaglandin and leukotriene synthesis. We studied 
the effect of a fish oil diet on an immune complex induced 
keratitis of the rabbit eye and compared the effects of this diet 
with the effects of a sunflower oil diet, rich in linoleic acid. 
Fish oil treated animals showed significantly less leukocyte 
infiltrate, neovascularization and corneal edema in comparison 
with sunflower oil fed rabbits. 
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12. Samenvatting 
Het effect van locale toediening van de fosfodiesterase-
remmer 3-isobutyl-methyl-xanthine (IBMX) werd bestudeerd bij een 
experimentele immuuncomplex uveitis in het konijnenoog. Deze 
ontsteking ontstaat na sensibilisatie met een intravitreale 
injectie van humaan-serum albumine (HSA) als antigeen. Intra-
veneuze toediening van dit antigeen daarna geeft aanleiding tot 
een bloed-kamerwater-doorbraak en leukocyteninfiltratie van het 
oog. Behandeling met IBMX 1% tweemaal daags gaf een significante 
bescherming van de bloed-kamerwater-barriere en een daling van 
het prostaglandine E2-gehalte van het kamerwater. Er was geen 
effect op het aantal geinfiltreerde leukocyten te zien. Het 
therapeutisch effect van IBMX werd vergeleken met het effect van 
lokale behandeling met het corticosteroid medrysone. 
Intrastromale injectie met HSA als antigeen in de cornea van 
het konijnenoog induceert corneaoedeem en een ringvormig leuko-
cyteninfiltraat gevolgd door neovascularisatie in het hoornvlies. 
Het effect van lokaal toegediende lipoxygenase- en cyclo-oxy-
genaseremmers en een PAF-acether-antagonist op deze keratitis 
werd bestudeerd. Op ditzelfde ziektemodel werd het therapeutisch 
effect van lokale en systemisch toegediende onverzadigde vetzuren 
geevalueerd. 
De lipoxygenaseremmers BAY 08276 en Rev 5901 en de cyclo-
oxygenaseremmer suprofen werden driemaal daags als 1% oogdruppels 
gegeven. Ogen behandeld met de lipoxygenaseremmers gaven een 
significante vermindering van het leukocyteninfiltraat, de 
neovascularisatie en het oedeem te zien. In ogen behandeld met 
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een cyclo-oxygenaseremmer verminderde het corneaoedeem en was de 
neovascularisatie minder lang aanwezig. Er werd geen invloed op 
de ernst van het leukocyteninfiltraat geconstateerd. 
Uit een aantal onverzadigde vetzuren kunnen prostaglandinen 
en leukotrienen gevormd worden. Afhankelijk van het het vetzuur 
hebben de daaruit gevormde prostaglandinen en leukotrienen andere 
biologische eigenschappen. Bij konijnen met immunogene keratitis 
werden arachidonzuur, gamma-linoleenzuur, dihomo-gamma-linoleen-
zuur (DHGL), eicosapentaanzuur (EPA) en akeleizuur als 0,5% oog-
druppels driemaal daags toegediend. EPA, DGHL, akeleizuur en 
gamma-linoleenzuur gaven een significante remming van hetzij 
leukocyteninfiltraat hetzij de oedeemvorming c.q. de neovascu-
larisatie te zien. Arachidonzuur had noch een stimulerende, noch 
een remmende invloed op het ontstekingsproces. Het remmend effect 
van deze vetzuren lijkt te verklaren door lokale remming van de 
vorming van prostaglandinen en leukotrienen uit arachidonzuur in 
de cornea. 
Thrombocyten activerende factor (platelet-activating factor; 
1-0-alkyl-2-acetyl-glyceryl-3-phosphocholine, PAF-acether) is een 
van de meest krachtige bloedplaatjesaggregerende stoffen. Naast 
andere biologische eigenschappen is het een belangrijke ontste-
kingsmediator welke onder andere een verhoogde vasculaire permea-
biliteit veroorzaakt. De PAF-acether-antagonist BN 52021 werd 
driemaal daags als 1% suspensie toegediend in een ziektemodel 
bestaande uit abrasio corneae en een immunogene keratitis. Na 
abrasio corneae was in de niet-behandelde ogen het corneaepitheel 
168 uur na de abrasio gesloten. In ogen behandeld met BN 52021 
was 6 uur na de abrasio minder corneaoedeem dan bij de niet-
behandelde ogen te zien. Dit verschil in oedeemvorming bleef 
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aanwezig gedurende het hele proces van epitheelregeneratie. Na 
sluiting van het corneaepitheel was de corneadikte hetzelfde als 
voor het experiment. Tijdens immunogene keratitis was bij ogen 
behandeld met BN 52021 de duur van het leukocyteninfiltraat en de 
mate van corneaoedeem significant verminderd ten opzichte van 
onbehandelde ogen, de corneaneovascularisatie werd niet door BN 
52021-behandeling beinvloed. 
Vetten van vis bevatten grote hoeveelheden eicosapentaanzuur 
en docosahexaanzuur. Deze vetzuren hebben een invloed op prosta-
glandinen- en leukotrienensynthese. We bestudeerden het effect 
van een visoliedieet op een immuuncomplex-geinduceerde keratitis 
van het konijnenoog. Dit dieet werd vergeleken met het effect van 
een zonnebloemoliedieet rijk aan linolzuur. Visolie-behandelde 
dieren lieten significant minder corneaoedeem, leukocyteninfil-
traat en corneaneovascularisatie zien vergeleken met zonnebloem-
olie-gevoede konijnen. 
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